Archive for the ‘Bone Marrow Stem Cells’ Category

Even though he had Covid-19, Sila Jio Boonklomjit, a five-year-old boy in Thailand, with covid-19 managed to save his sisters life. With the stem cells he donated for her bone marrow transplant.

Doctors only discovered Jio contracted the coronavirus the day before Jintanakan Jean Boonklomjit, his sisters urgent transplant.

Despite the challenges, which included quarantine restrictions placed on Jio on the eve of the transplant procedure. However the treatment was carried out successfully.

And it was done so without Jio passing the coronavirus to Jean.

While the experimental procedure first began in April, the bone marrow was only successfully transplanted on June23 at Ramathibodi Hospital.

Jeans case was believed to be the first successful stem cell transplant from a donor with active Covid-19, according to reports.

She was reported to be in a severe condition as she wasborn with thalassemia a genetic blood disorder that limits the bloods ability to carry oxygen.

There were also difficulties finding a suitable donor for Jean, which left Jio as their best hope, said Suradej Hongeng of the hospitals pediatrics department.

It was a long and uncertain road to this happy outcome, according to the doctor.

Jio and Jean were confirmed to be a genetic match in 2018. The hospital prepared for the transplantation procedure thereafter.

But with any medical procedures, there were certain complications and hurdles involved.

According to Suradej, the siblings young age were part of the difficulties faced during the procedure. Jeans chemotherapy procedure also caused her immune system to be compromised. That delayed the bone marrow transplant until this year.

Still, things turned out well in the end, and the five-year-old boy was applauded for saving his big sisters life.

Its as if my daughter is reborn and gets a new life, said the childrens father, Suchai Boonklomjit.

Jio has since recovered from Covid-19, which was believed to be transmitted from his mother, according to doctors in Thailand.

Thailands health department has reported on Monday that the Kingdom has gone 35 consecutive days without a local Covid-19 Coronavirus case. However health officials have confirmed 7 imported cases with Thai returnees.

The 7 imported covid-19 coronavirus cases brings the total number of infections in Thailand to 3,169 with 58 deaths since January. All the new cases were Thai nationals in quarantine. They recently returning from India and the US to Thailand.

There have been no local transmissions for 35 days Thailands health department said Monday.

Continued here:
Five Year-old Boy with Covid-19 Saves Sisters Life in Thailand - Chiang Rai Times

Summary

A review of 423 patients treated at MSK finds that most people with cancer dont fare any worse if they get COVID-19 than other people who are hospitalized for that infection.

In the early days of the COVID-19 pandemic, many doctors worried that people undergoing treatment for cancer would do particularly poorly if they became infected with the virus that causes the disease. Thats because treatments for cancer, especially chemotherapy, can lower a persons immune defenses and put them at higher risk for all kinds of infections.

But according to a new study from Memorial Sloan Kettering published June 24 in Nature Medicine, most people in active cancer treatment dont fare any worse if they get COVID-19 than other people who are hospitalized with the infection. Further research is needed to look at the effects of certain drugs mainly immunotherapies called checkpoint inhibitors, which did seem to make COVID-19 worse. But the researchers say their findings suggest that no one should delay cancer treatment because of concerns about the virus.

If youre an oncologist and youre trying to figure out whether to give patients chemotherapy, or if youre a patient who needs treatment, these findings should be very reassuring, says infectious disease specialist Ying Taur, one of the studys two senior authors.

Infectious disease expert Ying Taur has cared for many MSK patients who were hospitalized with COVID-19.

The study looked at 423 MSK patients diagnosed with COVID-19 between March 10 and April 7, 2020. Overall, 40% were hospitalized for COVID-19, and 20% developed severe respiratory illness. About 9% had to be placed on a mechanical ventilator, and 12% died. The investigators found that patients taking immunotherapy drugs called immune checkpoint inhibitors were more likely to develop severe disease and require hospitalization. But other cancer treatments, including chemotherapy and surgery, did not contribute to worse outcomes.

The big message now is clear: People should stay vigilant but not stop or postpone checkpoint immunotherapy or any other cancer treatment.

Factors that did make COVID-19 worse were the same as those seen in studies of people who didnt have cancer. We found that being older, as well as preexisting conditions like heart disease and diabetes, are all drivers of severe COVID-19 illness, says MSK Chief Medical Epidemiologist Mini Kamboj, the studys other senior author. This wasnt surprisingbecause these connections are well established.

Although the study wasnt large enough to make determinations about every treatment and every cancer type, patterns did emerge. Dr. Taur says there was initially great concern about people receiving high doses of chemotherapy for leukemia, especially those who had recently undergone bone marrow or stem cell transplants. Thats because transplants require a persons entire immune system to be wiped out with chemotherapy before they receive new blood cells, leaving them susceptible to all kinds of infections.

Surprisingly, though, Dr. Taur cared for recent transplant recipients who were infected with COVID-19 but didnt have any symptoms. If you think about it more, it makes sense, he says. Most of the complications seen in people with COVID-19 seem to be caused by the bodys immune response to the virus.

On the other hand, immunotherapy drugs called checkpoint inhibitors work by freeing up the immune system to attack cancer. Patients receiving these agents may develop a more robust reaction to the virus that causes COVID-19. This may explain why this study observed higher rates of complications in people with COVID-19 infection who were treated with checkpoint inhibitors.

Even with immune checkpoint inhibitors, though, these findings should not affect whether patients get treated. Everyone who needs these drugs should still receive them, Dr. Kamboj says. Its just important for doctors to be extra vigilant about testing and monitoring for the virus and for people with cancer to take extra precautions to avoid infection.

A study published in May 2020 by MSK immunotherapy expert Matthew Hellmann focused exclusively on people with lung cancer who got COVID-19. The researchers didnt find the same risks from immune checkpoint drugs as this Nature Medicine study. More research in this area is needed.

Dr. Kamboj notes that one aspect of this research that sets it apart from other studies is that it included at least 30 days of follow-up after a COVID-19 diagnosis. Also, it reported severe respiratory illness as a main outcome rather than death.

Having that follow-up time is something that a lot of other studies have not included because everyone is in a rush to get their data out. In addition, reporting death rates can overestimate infection-related mortality, especially in the early phase of an epidemic, Dr. Kamboj says. Also, the clinical spectrum and course of this disease is still not fully understood, especially in people with cancer. We wanted to give patients enough time to recover and make sure they didnt need to be readmitted to the hospital.

Even with immune checkpoint inhibitors, though, these findings should not affect whether patients get treated. Everyone who needs these drugs should still receive them.

She adds that another strength of the study is that patient outcomes were not affected by constraints caused by a lack of space or supplies even though MSK is in the heart of the COVID-19 epicenter in New York City, where other hospitals faced overcrowding and other issues. This gave researchers a true picture of how cancer patients fare with COVID-19. We saw a surge during the peak of the epidemic in New York, but everyone got the care they needed, Dr. Kamboj explains. We had enough ventilators for everyone who needed them. We never had to make decisions about who to admit to intensive care because of a lack of critical equipment.

Drs. Taur and Kamboj agree that this is just one of many studies that will need to be done on the connections between cancer and COVID-19. We still need to find out more. We need to look at the connections between COVID-19 and particular types of cancer as well as outcomes related to specific chemotherapy drugs, Dr. Taur concludes. But the big message now is clear: People should stay vigilant but not stop or postpone checkpoint immunotherapy or any other cancer treatment.

See more here:
Should You Delay Cancer Treatment Because of COVID-19? Study Says Most Treatments Dont Worsen Coronavirus Infection - On Cancer - Memorial Sloan...

NantKwest (NASDAQ:NK) has been one of my best investments over the past year and looks to be ready to move higher following another positive data for cancer and development of a COVID-19 vaccine. Recently, the company's CEO, Dr. Patrick Soon-Shiong "PSS", has been on some news segments discussing some of their fresh cancer readouts and the company's potential to develop a premier COVID-19 vaccine. It looks as if their activated NK cell platform is able to be implemented in multiple disciplines of medicine and could be a vital component in future therapeutics. With the share price rising roughly 1000% since my first buy, I have to make some decisions about how I intend to manage my NK position in the coming days, weeks, months, and years. One wrong move and I could miss the chance to bank some profits or possibly sell too early and miss out on future growth.

First, I will take a look at the recent pipeline updates and data. Second, I will discuss why I am so bullish after the recent offering. Finally, I intend to discuss my course of action that will alleviate both of my concerns.

Out of all of NantKwest's clinical-stage engineered natural killer cell programs, I have been waiting to see some data from their first-in-class PD-L1 t-haNK candidate. The company's PD-L1 t-haNK is created using a haNK cell that has PD-L1 CAR, which will provide an innovative method for targeting PD-L1 tumors. NantKwest recently revealed some positive data for in-vivo models of 15 solid tumors in treatment-refractory cancer types and demonstrated activity in the hypoxic environment.

This is significant because healthy donor NK cells are typically impaired in hypoxic environments, so NantKwest's proprietary off-the-shelf NK cells have an advantage over our own NK cells and potentially other NK therapies. Essentially, NantKwest's NK cells are able to work in a tumor environment that typically disables or nullifies our own NK cells' ability to attack the tumor. In addition, the PD-L1 t-haNK cells were able to show some efficacy in infamously treatment-refractory cancers such as triple-negative breast cancer, lung, and urogenital cancer. PSS believes that their highly targeted NK cell therapies have the potential to take on these highly resistant tumors that have "stem-like" cells, which can be impervious to chemotherapy and checkpoint therapies. In fact, the company reported their first patient with advanced metastatic pancreatic cancer treated with PD-L1 t-haNK has revealed a durable complete response.

Not only am I impressed with the company's ability to create one of these Checkpoint CAR-NK-like cells, but the fact the therapy was able to produce a durable complete response in an advanced metastatic pancreatic cancer patient has turned me into a perma-bull. It looks as if PSS has essentially fused the immunotherapy and cell therapy to create a cutting-edge cancer therapeutic. Once again, PSS and NantKwest have revealed a candidate that could define the next generation of oncology therapeutics.

NantKwest and ImmunityBio are working in collaboration on vaccines and therapeutics to fight COVID-19. ImmunityBio will be working on the development of a vaccine and natural killer cell activation, with their immunomodulators. NantKwest will be focusing on their off-the-shelf, cell-based therapeutics to develop therapeutics for COVID-19. It appears that the goal is to develop a broad array of products to prevent and treat various stages of infection or tissue damage.

So far, ImmunityBio and NantKwest have developed "immunomodulator regimens" for COVID-19 for mild, moderate, severe, and critically ill state (Figure 1). In the early-moderate stage of the disease, the two companies are planning on a clinical trial of ImmunityBio's Il-15 'superagonist' N-803. In addition, they are planning another trial using NantKwest's haNK cell, or haNK in combination with convalescent plasma. In the severely ill, the company is looking to employ bone marrow-derived allogeneic mesenchymal stem cells "BM-Allo-MSC" to diminish the "cytokine storm". These cells can be grown in ImmunityBio's automated GMP-in-a-Box in roughly 7-9 days, which could allow providers to create these therapeutics in-house and essentially on-demand. NantKwest has filed an IND and anticipates beginning trials in the near future.

Figure 1: NantWorks COVID-19 Programs (Source: NantKwest)

In terms of a vaccine, ImmunityBio has a second-generation Ad5 platform that will produce a vector that is immunologically "quiet" and could allow patients who were previously vaccinated with an Ad5 vaccine. In addition, ImmunityBio's vaccine goes after both the spike "S" protein and the nucleocapsid "N" protein in order to induce antigen-specific T-cell immunity. This is significant because it is the only known COVID-19 vaccine that is targeting both, which could allow an extended immunity to the virus compared to vaccines which are only targeting the spike proteins. What is more, this Ad5 platform has demonstrated humoral and cell-mediated immunity for several other deadly viruses such as H1N1, HIV, Chikungunya, and Zika. Therefore, we should expect ImmunityBio's vaccine to show some efficacy against COVID-19 and perhaps be the premier vaccine.

Once COVID-19 hit the United States and the healthcare industry started pumping out vaccines and therapeutics, I almost instantly thought "when is Patrick Soon-Shiong going to unveil his COVID-19 solution?" NantWorks has repeatedly produced some extremely impressive product candidates for just about every major issue in healthcare. The minute the company released their press release revealing their candidates, I was looking for the market to have an immediate response both in share price and an increase in chatter. Unfortunately, it appears as if the NantWorks structure has once again caused some confusion, and the response was quite mute compared to other COVID-19 plays. It is possible that NantKwest has a therapy that can target the virus with minimal safety concerns. Is the market missing NantKwest again? Once again, it looks as if ImmunityBio has some of the primary cogwheels that are required for their COVID-19 programs, and NantKwest is just a minor player with very little to claim in the end.

Indeed, NantKwest and their NK cells appear to have a critical role in many of the NantWorks programs. However, I didn't feel reassured in the recent COVID-19 press releases. In fact, I felt as if PSS was using NantKwest's IR as a vehicle to get ImmunityBio's (a private NantWorks company) pipeline some public exposure. As a result, I would like to see some more details about NantKwest's involvement in these collaboration programs.

Back on June 24th, NantKwest announced that they intended to execute a public offering with Piper Sandler & Co., for 7.41M shares of common stock at $9.50 per share, with Piper Sandler & Co. purchasing 3.7M at $8.93 per share. What is more, PSS agreed to purchase 3.71M shares at $12.12 per share. The net proceeds are anticipated to be around $76.4M, which will be added to roughly $17M in cash and cash equivalents the company had at the end of Q1.

Typically, I am not incredibly excited about a public offering due to a negative reaction in the share price and shareholder dilution. However, I am now very bullish following the recent offering as a result of PSS willing to purchase shares at market value. It is often quite bullish to see insiders buying common stock, but it isn't common to see insiders looking buy at 52-week highs. Now, I am looking to join PSS and average up in the coming days or weeks once the technical analysis gives me the green light, and the recent volatility in the market subsides.

Admittedly, I decided to reduce my position during the January spike, but I was willing to reapply those profits once the stock was able to break out of its downtrend and cross above 200-day EMA (Green Circle on Figure 22). Now, I am waiting to see where the market is going to NK in the coming days before adding to the position. I am keeping an eye on several indicators and trend line to give me the signal to click the buy button.

Figure 2: NK Daily (Source: Trendspider)

Looking at the daily chart, we can see the stock had no problem busting through its previous 52-week high. However, the chart shows a double-top with two inside bars and an abrupt sell-off coming after the offering news. The combination of a strong bullish move followed by a negative news event will make this addition a bit tricky. I am going to wait and see if the share price is able to bounce off the red uptrend line and bust through the recent green downtrend line. Once the stock makes a decision, I am going to turn to the RSI to see if the share price remains above the green trend line and is still trading above $8.40 per share. If these conditions line up, I will make a small addition to my NK position in anticipation the stock will make another leg higher. If the share price breaks down and the RSI trend is broken, I will sell roughly half of my position and wait to see if the stock wants to retest the 200-day EMA before considering an addition.

I expect to make a few more small additions to my NK position over the course of 2020 and will leave the year with a respectable position. However, I am not going to "go-all-in" until I figure out how NantKwest will ultimately land in the NantWorks hierarchy.

Disclosure: I am/we are long NK. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read the original here:
NantKwest: The Market And The Government Are Missing Out On This Blockbuster - Seeking Alpha

By: Lifestyle Desk | New Delhi | Updated: June 27, 2020 12:09:31 pm Heres everything to know about the blood disorder. (Source: Getty Images/Thinkstock)

Sickle cell disease (SCD) is an inherited group of blood disorder which is genetic in nature. It is usually transferred from parents to the child during birth i.e. both the parents can be carries of SCD. Healthy RBCs are round in shape, which moves through small blood vessels and carries oxygen to all parts of the body. In someone who has SCD, the RBC becomes sticky and hard and start to look like C- shaped similar to that of a farm tool sickle. The sickle cells die early, which causes a constant shortage of RBC, which leads to low oxygen carriers in the body, mentioned Dr Rahul Bhargava, director and head, haematology and bone marrow transplant, Fortis Memorial Research Institute, Gurugram. Also, when sickle cells travels they tend to get stuck in small blood vessels and restrict the blood flow. This can cause pain in the joints, chest and other serious problems such as stroke, acute chest syndrome and infections.

Anaemia

SCD can lead to shortage of RBC which makes the patient anaemic. It can lead to less oxygen supply in the body causing fatigue.

Episodes of pain. SCD patients suffer from episodes of periodic pain. Sickle-shaped blood cells can block the flow of blood which in tiny vessels of abdomen, chest and joints, thus leading to pain.

Feet and hands swelling

Sickle-shaped RBC can block then flow of blood which can cause swelling in the hands and feet.

Frequent infections

Sickle cells can damage the spleen and make the person vulnerable to diseases and infections. Vaccination is usually prescribed in childhood to keep infections at bay.

Delayed growth or puberty

RBC is the carrier of oxygen and other nutrients. With low RBC, there is no enough oxygen in the body which can slow the growth in infants and children which leads to delayed puberty in children.

Vision problems

Vision is affected when the flow of blood is affected.

SCD can lead to a lot of complication, including Stroke, acute chest syndrome, pulmonary hypertension, organ damage, blindness, leg ulcers and more such complications.

SCD can be diagnosed with a simple blood test. Parents are advised to get the screening done before conceiving as it is transmitted from parents. For newborns, the test is done in the hospitals as a routine screening. There is no single treatment for SCD patients and it varies from patient to patient on the basis the symptoms. Before starting any medication, consult a haematologist who specialises in blood disorders.

The only cure for SCD is getting a bone marrow transplant (BMT), which is a procedure to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Stem cells are easily taken from the donor and planted in the recipient. After the BMT procedure, the patient can lead a healthy and normal life.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Lifestyle News, download Indian Express App.

IE Online Media Services Pvt Ltd

See the rest here:
Sickle Cell Disease: All you need to know - The Indian Express

Dana-Farber Patient Recovering Well After Cancer and the Coronavirus

Pam Dobay is a warrior. In the last three years, the 67-year-old has dealt with a cancer diagnosis and stem cell transplant before recently contracting the coronavirus.

None of it was easy, but today, Dobay is recovering at home. She says she cannot begin to express the gratitude she feels towards everyone who has cared for her, including her Dana-Farber care team and her family.

When this is all over, I want to show everyone at Dana-Farber what they did, and thank them for everything, says Dobay.

A Blood Cancer Diagnosis

In February 2018, Dobay was diagnosed with myelofibrosis, a blood disorder in which the bone marrow is unable to produce healthy red blood cells. Dobays primary care physician first worried something wasnt right after her test results from routine blood work came back abnormal. Myelofibrosis is a precursor condition for leukemia, meaning it puts those who are diagnosed at a much higher chance of developing the disease.

Dobay, who lives in Holbrook, MA, was placed under the care ofCorey Cutler, MD, MPH, medical director of theAdult Stem Cell Transplantation Programat Dana-Farber/Brigham and Womens Cancer Center. Initially, she was given blood transfusions to help her body compensate for the bone marrows inability to produce red blood cells. This treatment is not designed to be a permanent fix, despite being highly effective for a short period of time: Eventually, Dobay would need a bone marrow transplant.

In September 2018, just six months after her diagnosis, Dobay underwent areduced-intensity transplant(sometimes referred to as a mini-transplant). Mini-transplant patients receive lower doses of chemotherapy than are used in a full-intensity transplant, and in general, receive no radiation therapy. The reduced-intensity procedure was developed for older patients and others who often cant tolerate the harsh side effects of full-intensity treatments.

The procedure still proved to be difficult for Dobay, who ended up in the intensive care unit (ICU) due to complications. This was a possibility her care team had prepared for, and slowly, her condition improved. While she still has some symptoms of chronic graft-versus-host disease (GVHD), she and her family including Robert Dobay, her husband of 45 years hoped this would be her toughest test.

This article was originally published on June 18, 2020, by Dana-Farber Cancer Institute. It is republished with permission.

Follow this link:
Recovering from Cancer, a Stem Cell Transplant and Coronavirus - Cancer Health Treatment News

Post COVID-19 Impact on Cancer Stem Cell Market

With the emergence of the COVID-19 crisis, the world is fighting a health pandemic as well as an economic emergency, almost impacting trillions of dollars of revenues.

Research Dive group of skilled analysts provide a solution to help the companies to survive and sustain in this economic crisis. We support companies to make informed decisions based on our findings resulting from the comprehensive study by our qualified team of experts.

Our study helps to acquire the following:

Well help you fight this crisis through our business intelligence solutions.

Connect with Our Analyst to Contextualize Our Insights for Your Business: https://www.researchdive.com/connect-to-analyst/32

Pre COVID-19 Analysis on Cancer Stem Cell Market

According to a study by the World Health Organization (WHO), cancer is the cause for every one death out of six occurrences. Growing cases of cancers such as breast cancer, lung cancer and others due to poor diet patterns, air pollution, sexually transmitted infections, alcohol consumption. Other types of cancer are liver cancer, pancreas cancer, brain cancer, bladder cancer, colon, and blood cancer. The most common cures for cancer are chemotherapy, radiation, and surgeries. These procedures have an adverse effect on the human body. High doses of radiation and chemotherapy destroy the blood-forming stem cells. Stem cells are the soft tissues of the bone that grow inside the bone marrow. Stem cell transplants restore the blood-forming stem cells. These stem cells grow into platelets, RBCs, and WBCs that are required by the body to fight illness and provide oxygen. Usually, these transplants are done within the family to find the closest match.

Check out How Stem-cell based cancer segment is will generate revenue of $896.9 Mn by the year of 2026. Click here to know more in details @ https://www.researchdive.com/purchase-enquiry/32

According to a study,Cancer Stem Cells Marketby Research Dive, the global market will surpass $1,722.7 million by 2026. Rising number of cancer patients, coupled with the latest advancements in cancer stem cells will upsurge the global market by the year 2026.

Cancer Stem Cells Market Segmentation by Cancer Form

Regional Investment Opportunities:

North America cancer stem cell market is generated revenue of $365.64 million by end of 2018 and is anticipated to rise at 10% CAGR during the analyzed period. Asia-Pacific market registered a growth rate of 11.2% during the forecast period. This market will surpass $367.68 million by 2026, growing from $157.26 million in 2018. China, India, and Japan are the key contributors to the growth of regional market.

Cancer Stem Cells Market Segmentation by Application

Stem Cells for Cancer

Cancer stem cells or CSCs are a subpopulation of cells that has the driving force of carcinogenesis. Characteristics of cancer stem cells are proliferation, and differentiation capabilities and distinctive self-renewal. These characteristics play a vital role in many stages of cancer such as cancer initiation, drug resistance, progression, maintenance, and metastasis or relapse. CSCs have traits that are linked with normal stem cells and are found within hematological cancers or tumors.

Check out How Cancer stem cells market for breast cancer is projected to hold a dominant share, owing to the genetic influences & alcohol use @ https://www.researchdive.com/download-sample/32

Stem Cell-based therapy

According to the World Health Organization (WHO), the most common cause of deaths in women diagnosed with cancer is breast cancer.Global cancer stem cells marketis projected to reach up to $896.9 million by the end of 2026 as the stem cell-based cancer therapy and targeted cancerous stem cell therapy are advancing in the medical field. Cell-based therapy is split into allogenic Stem Cell therapy and autologous Stem Cell therapy. Allogenic Hematopoietic Stem Cell Transplantation is more beneficial than the autologous Hematopoietic Stem Cell Transplantation for Breast cancer based on different aspects such as cancer-free graft & immune-mediated Graft vs Tumor effect mediated by the donors immune cell.

Successful engraftment rates together with lesser transplant-related mortality and the presence of Graft vs Tumor effect made allogeneic Hematopoietic Stem Cell Transplantation with Reduced Intensity conditioning is the better choice option for the treatment of multiple solid tumors. Due to aforesaid aspects, it is anticipated that allogenic cell therapy will be the rising point for the cancer stem cell market. The global market for stem cell-based cancer therapy is estimated to grow at 9.3% CAGR in 2026 from $440.3 million in 2018.

Advancements in Cancer Stem Cell Transplantation

The prime reason for such huge growth is majorly owed to the rising developments in stem cell therapy of the Asia-Pacific and Europe region. Physicians in Canada are endorsing and promotion of stem cell interventions, which are ethical, legal, and regulatory. U.S. and Canada are leading the cancer stem cell market in the North America region. The North America market is expected to grow over the forecast period and is further projected to generate revenue of $783.8 million by 2026 from its market value of $365.6 million in 2018. While the Asia-Pacific Cancer Stem Cells Market is anticipated to rise to $367.7 Million till 2026 and the Europe Cancer Stem Cells Market is anticipated to generate revenue of $419.5 Million till 2026. Amongst these regions, the Asia-Pacific region is anticipated to be the fastest-growing region for cancer stem cells market. Governing bodies of India, Japan, and other countries are promoting Stem cell transplant by constructing new infrastructure and enlisting new strategies for the launch of centers of stem cells.

The major players in the global cancer stem cell market are introducing several strategies to reinforce their presence in the market

Get Access to Full Report (TOC, Figures, Chart, etc.) @ https://www.researchdive.com/32/cancer-stem-cells-market

Segmentation Growth Definition of Cancer Stem Cells Market:

Breast cancer market will surpass $295.0 million in the year 2026, and is anticipated to rise at 10.4% CAGR during the estimate period. The cancer stem cells market for bladder is anticipated to increase at 11.2% CAGR, and will surpass $275.8 million by 2026, rising from $117.9 million in 2018. Global market for stem cell based cancer therapy was $440.3 million by end of 2018 and is anticipated to grow at 9.3% CAGR. This is majorly due to the rising advancements in stem cell therapy of Asia-Pacific and Europe region.

About Us:Research Dive is a market research firm based in Pune, India. Maintaining the integrity and authenticity of the services, the firm provides the services that are solely based on its exclusive data model, compelled by the 360-degree research methodology, which guarantees comprehensive and accurate analysis. With unprecedented access to several paid data resources, team of expert researchers, and strict work ethic, the firm offers insights that are extremely precise and reliable. Scrutinizing relevant news releases, government publications, decades of trade data, and technical & white papers, Research dive deliver the required services to its clients well within the required timeframe. Its expertise is focused on examining niche markets, targeting its major driving factors, and spotting threatening hindrances. Complementarily, it also has a seamless collaboration with the major industry aficionado that further offers its research an edge.

Contact us:Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US)Toll Free: +1-888-961-4454E-mail: [emailprotected]LinkedIn:https://www.linkedin.com/company/research-dive/Twitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-Dive-1385542314927521Blog:https://www.researchdive.com/blogFollow us:https://marketinsightinformation.blogspot.com/

Originally posted here:
Global cancer stem cells market is projected to reach up to $896.9 million by the end of 2026 - Cole of Duty

CRANFORD, N.J., June 26, 2020 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the Company has received a written response from the U.S. Food and Drug Administration (FDA) in regards to its pre-investigational new drug (PIND) application for its induced mesenchymal stem cells (iMSCs) to treat and reduce the severity of acute respiratory distress syndrome (ARDS) in patients with COVID-19.

The FDA acknowledged that the Company could apply for fast track designation and also provided Citius with the chemistry, manufacturing, and control (CMC) requirements for the proposed trials. The Company plans to initiate actions on the FDA's recommendations and follow up with the FDA with an Investigational New Drug (IND) application under the Coronavirus Treatment Acceleration Program (CTAP).

Myron Holubiak, Chief Executive Officer of Citius, commented, "We appreciate the FDA's thoughtful guidance on our unique, allogenic mesenchymal stem cells derived from induced pluripotent stem cells (iPSCs). We understand that iPSC-derived stem cells are not the same as adult-donor derived cells and, therefore, would require different proof of concept studies. Since we believe in the advantages of iPSC MSCs over donor-derived cells, we intend to develop assays recommended by the FDA and demonstrate the safety of these MSCs in our preclinical studies. We are committed to the successful completion of the required clinical trials to provide an effective and safe therapy for ARDS due to COVID-19."

About Citius Pharmaceuticals, Inc.Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visitwww.citiuspharma.com.

About Citius iMSCCitius's mesenchymal stem cell therapy product is derived from a human induced pluripotent stem cell (iPSC) line generated using a proprietary mRNA-based (non-viral) reprogramming process. The iMSCs produced from this clonal technique are differentiated from adult donor-derived MSCs (bone marrow, placenta, umbilical cord, adipose tissue, or dental pulp) by providing genetic homogeneity. In in-vitro studies, iMSCs exhibit superior potency and high cell viability. The iMSCs secrete immunomodulatory proteins that may reduce or prevent pulmonary symptoms associated with acute respiratory distress syndrome (ARDS) in patients with COVID-19. The Citius iMSC is an allogeneic (unrelated donor) mesenchymal stem-cell product manufactured by expanding material from a master cell bank.

About Acute Respiratory Distress Syndrome (ARDS)ARDS is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. ARDS is a rapidly progressive disease that occurs in critically ill patients most notably now in those diagnosed with COVID-19. ARDS affects approximately 200,000 patients per year in the U.S., exclusive of the current COVID-19 pandemic, and has a 30% to 50% mortality rate. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

About Coronavirus Treatment Acceleration Program (CTAP)In response to the pandemic, the FDA has created an emergency program called the Coronavirus Treatment Acceleration Program (CTAP) to accelerate the development of treatments for COVID-19. By redeploying staff, the FDA is responding to COVID-19-related requests and reviewing protocols within 24 hours of receipt. The FDA said CTAP "uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful." In practice, that means developers of potential treatments for COVID-19 would benefit from an unusually faster track at the FDA to shorten wait times at multiple steps of the process.

Safe Harbor

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risk of successfully negotiating a license agreement for a potential ARDS therapy with Novellus, Inc. within the option period; the ability to access the FDA's CTAP program for our planned ARDS therapy; risks associated with developing our product candidates, including any licensed from Novellus, Inc., including that preclinical results may not be predictive of clinical results and our ability to file an IND for such candidates; our need for substantial additional funds; risks associated with conducting our Phase 3 trial for Mino-Lok, including completing patient enrollment, opening study sites and achieving the required number of catheter failure events; the estimated markets for our product candidates, including those for ARDS, and the acceptance thereof by any market; risks related to our growth strategy; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to attract, integrate, and retain key personnel; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Andrew Scott Vice President, Corporate Development (O) 908-967-6677 x105[emailprotected]

SOURCE Citius Pharmaceuticals, Inc.

Home

View original post here:
Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute...

The research report by The Insight Partners, titled, Cell Therapy Market, offers a comprehensive analysis of key growth drivers, key segments, development strategies, market opportunities, and competitive landscape. This study offers detailed insights for market players, investors, stakeholders, and new entrants to understand the industry dynamics and determine strategic steps to gain a competitive advantage.

Cell therapy (CT) is the process of transplanting human cells to replace or repair damaged tissue or cells. Various methods can be used to carry out cell therapy. For instance, hematopoietic stem cell transplantation, also known as bone marrow transplant, is the most widely used cell therapy. It is used to treat a variety of blood cancers and blood-related conditions.

Download PDF Brochure at: https://www.theinsightpartners.com/sample/TIPRE00009666/

Major Players Included in this report are as follows

Kolon TissueGene, Inc. MEDIPOST JCR Pharmaceuticals Co. Ltd. Stemedica Cell Technologies, Inc. Osiris Therapeutics, Inc. NuVasive, Inc. Fibrocell Science, Inc. Vericel Corporation Cells for Cells Celgene Corporation

Cell Therapy Market: Regional analysis includes:

This report on Cell Therapy Market delivers an in-depth analysis that also comprises an elaborate assessment of this business. Also, segments of the Cell Therapy Market have been evidently elucidated in this study, in addition to a basic overview pertaining to the markets current status as well as size, with respect to the profit and volume parameters. The study is ubiquitous of the major insights related to the regional spectrum of this vertical as well as the companies that have effectively gained a commendable status in the Cell Therapy Market.

The global cell therapy market is segmented on the basis of therapy type, product, technology, application, end user. Based on the therapy type the market is classified as autologous, and allogeneic. Based on product the market is segmented as equipment, consumables, software and services. Based on technology the market is segmented as somatic cell technology, cell immortalization technology, viral vector technology, genome editing technology, cell plasticity technology, and three-dimensional technology. Based on application the market is classified as oncology, cardiology, orthopedic, wound management and others. And based on end user the market is divided into hospitals, regenerative medicine centers, and research institutes.

The Cell Therapy Market research covers an exhaustive analysis of the following data:

Historical and future growth of the global Cell Therapy Market.

Segmentation of the Cell Therapy Market to highlight the growth prospects and trends impacting these segments.

Changing consumption behavior of customers across various regions.

Regional analysis on the basis of market share, growth outlook, and key countries.

Agreements, product launches, acquisitions, and R&D projects of different Cell Therapy Market players.

The Cell Therapy Market research addresses critical questions, such as

Why is region surpassing region in terms of value by the end of 2027?

How are the consumers using Embolization Devices for various purposes?

Which players are entering into collaborations in the market of the Embolization Devices?

At what rate has the global Cell Therapy Market been growing throughout the historic period?

In terms of value, which segment holds the largest share?

Purchase Copy of This Report at:https://www.theinsightpartners.com/buy/TIPRE00009666/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

Contact Us:

Call: +1-646-491-9876

Email:[emailprotected]

Follow this link:
Cell Therapy Market Top Manufacturers, Industry Size, Challenges, Drivers, Countries, And Technology Forecast To 2027 | Stemedica Cell Technologies,...

Whoever would have thought that the turn of a new decade would bring such a cataclysmic event to our world? Our economy was humming along. Times were good, and business was booming. Then along comes a pestilence in the form of a microscopic virus that has shaken our world to its core.

Tens of thousands of Americans have died. Hundreds of thousands have become ill. Millions have lost their jobs. And tens of millions have been isolated and socially distanced from friends and loved ones. History will look back on the Covid-19 pandemic as a turning point in our lives.

And while all of this has been going on, manufacturers continue to produce goods, warehouses process orders, trucks roll and deliver, and supply chains continue to function.

It has not been without a hitch, but supply chain has certainly been among the few bright spots during the pandemic. Finally, every American is aware of what supply chain professionals do each and every day without fanfare. Warehouse workers and drivers continue to show up for work, risking their health and their emotional well-being to keep freight moving.

In the following stories, we salute some of the many individuals and companies who have used their talents and resources to bring healing and hope, deliver comfort, and save lives during the Covid-19 crisis. We thank these unsung heroes who have quietly gone about their work to make sure the rest of us have what we need to make life appear almost normal.

Click one of the headlines below to skip ahead to a particular story.

Back to index

Stepping up their use of technology is one of the many ways logistics firms are meeting volatile business conditions brought on by the Covid-19 pandemic. Fort Wayne, Indiana-based Circle Logistics and White Plains, New York-based Capital Logistics are two examples of companies digging deeper into visibility tools to help monitor and manage freight shipments, especially for critical food and medical supply chains.

Both companies said this spring they were using Descartes Systems Groups MacroPoint real-time freight visibility solution to track critical loads for customers such as the Federal Emergency Management Agency (FEMA) and major grocery brands. Circle Logistics said it shifted its entire transportation network to manage a 700% increase in volume from customers moving critical freight, including personal protective equipment (PPE), respirators, cots for FEMA, and grocery loads. Company leaders said the platform allows it to better track the movement of goods under volatile conditions.

At Capital Logistics, leaders are also integrating Descartes Aljex cloud-based transportation management system (TMS) to manage volatility. Designed for freight brokers, the system automates planning, freight tendering, and dispatching as well as back-office functions including accounting, invoicing, and reporting. The integration with MacroPoint provides real-time freight visibility to automatically track loads, greatly reducing the manual efforts for track-and-trace teams, according to Descartes.

As our customers focus on keeping food supply chains functioning, having real-time visibility into the status of critical freight has increased our ability to keep pace with the unpredictable demand grocery stores are experiencing, Greg Ackner, vice president at Capital Logistics, said in late April. In one case, we went from moving two to three truckloads of milk per week to distribution centers serving multiple states to 50 to 60 truckloads per week.

Back to index

Forklift vendor Combilift is stepping up to address the shortage of medical equipment for treating Covid-19 patients by developing a splitter device that turns one ventilator into multiple ventilation stations.

Monaghan, Ireland-based Combilift used its resources in engineering and software design to pivot from the material handling sector to create the Combi-Ventilate, saying the unit will address the requirements of medical professionals in the Covid-19 emergency.

The Combi-Ventilate uses standard pipes and fittings for easy assembly, offers individual patient filters that prevent cross contamination, and supports dedicated computer screens for each patients vital information. The device is designed as an attachment that can be added to any brand of ventilator, installed easily into a hospitals intensive care unit (ICU), and purchased for a fraction of the cost of a standard ventilator, the firm said.

Back to index

The International Foodservice Distributors Association (IFDA) and FMI-Food Industry Association are partnering to help keep store shelves stocked amid the coronavirus pandemic. In March, the groups announced a partnership that aims to match food-service distribution companies that have excess product, warehouse space, and transportation capacity with food retailers and wholesalers in need of assistance, the associations said.

The partnership addresses the issue of excess product and capacity caused by the closing of restaurants, schools, and other businesses with retailers and wholesalers seeking to replenish store shelves more quickly. IFDA and FMI are gathering information from their members and matching capacity to need geographically, essentially functioning as a clearinghouse for contact information, according to IFDA spokeswoman Meghan Cieslak. She emphasized that the program aims to help fill demand for products but will also help fill demand for trucks, drivers, warehouse staff, warehouse storage, and similar needs.

Back to index

The Illinois-based material handling equipment dealer MH Equipment has used its corporate charity program to support several initiatives during the economic shutdowns and shortages caused by the Covid-19 pandemic.

First, the firm launched a campaign to address food shortages faced by community food banks and pantries during the coronavirus emergency. The companys Purpose Unites program allows employees to automatically deduct part of their paychecks to support local food banks. Along with donations from the companys His First Foundation charitable program, the effort raised nearly $187,000 across 33 office locations in just four days.

Second, the companys charity arm paid many of MH Equipments own employees to perform volunteer community service, using spare time they had available due to a drop in demand during the recession. MH Equipment compensated them for more than 4,000 hours of volunteer community service time across several Midwest states throughout the month of April. Those tasks included helping food banks with loading/unloading trucks, meal delivery, and packaging; making masks; mowing yards for the elderly and for nonprofit organizations; and using their technical skills to assist with light mechanical work on fire engines at volunteer fire departments.

Back to index

Truck drivers moving in and out of hot zones to perform essential work are receiving personal protective equipment (PPE) thanks to a collaboration between DDC FPO, a back-office partner for the transportation industry, and Truckers Emergency Assistance Responders (TEAR), a 501c3 nonprofit organization founded with the mission to help truck drivers in distress.

TEAR has built and deployed a network of corporate sponsors and volunteers to source, assemble, and distribute PPE kits to truck drivers on the front lines. Delivered at truck stops and rest areas, each PPE kit includes masks, hand sanitizer, gloves, antiseptic wipes, and snacks. The drivers are so appreciative, TEAR leader Desiree Wood said. They spend all day by themselves and arent used to receiving anything for free, let alone being recognized. They are thrilled to receive the kits.

Back to index

Supply chain technology provider Trimble Inc. has launched a free web app that displays truck-stop status and amenity information, allowing truck drivers to find essential break locations, showers, and restaurants.

The information comes as many break locations have closed completely or have shuttered certain amenities during the coronavirus crisis. Currently available on desktop or mobile devices in North America only, the Covid-19 Safe Haven Web App is intended to help the transportation community find out which locations are closed and which conveniences are open. Drivers can also use the platform to find Walmart locations with overnight parking, view live traffic and weather reports, and help their peers by reporting location closings.

Back to index

E-commerce retailer Amazon.com Inc. has teamed up with medical device manufacturer Boston Scientific to deliver donated face shields to health-care facilities around the U.S. fighting the Covid-19 pandemic.

Health-care volunteer coalition GetUsPPE organized the effort, under which Boston Scientific mobilized employees at a dozen sites to produce and donate the personal protective equipment (PPE), while Amazon offered logistics support. Amazon provided space on its trailers to deliver the shields from Boston Scientific to local delivery stations, where Amazon associates have worked with delivery service partners in Chicago, Detroit, and the Washington, D.C./Baltimore metro areas to deliver the face shields to hospitals and clinics.

Back to index

Job training nonprofit group Goodwill of South Florida has converted a portion of its sewing operations to manufacture 20,000 masks for employees at transportation and logistics company Ryder System Inc. The initiative extends a long relationship between the two organizations, since company founder James Ryder was also one of three founders of Goodwill some 60 years ago, David Landsberg, CEO of Goodwill of South Florida, said in a release.

The masks are being used to protect Ryders essential employees as they support the flow of goods and services needed in the fight against Covid-19. Each mask is made with camouflage material on the outside, a softer fabric on the inside, and elastic ear loops.

Back to index

Automaker Kia Motors America is donating personal protective equipment (PPE) to hospitals and medical facilities during the Covid-19 crisis. The face shields are assembled at its Kia Motors Manufacturing Georgia plant in West Point, Georgia, and the brand plans on donating a total of 300,000 face shields nationwide.

A group of company volunteers called Telluriders recently delivered face shields to Morristown Medical Center/Atlantic Health in Morristown, New Jersey. The deliveries were part of Kias Accelerate the Good initiative, which includes ongoing face shield donations to medical facilities in New Jersey, Southern California, and Georgia.

Back to index

Beer maker Sierra Nevada Brewing has donated some of its food laboratory resources in Chico, California, to making a critical component used in tests for detecting Covid-19 infections.

Sierra Nevada is using its quality assurance labusually dedicated to testing beer for unwanted bacteria and wild yeastfor creating the viral transport medium that is in short supply for enabling coronavirus tests. The medium is used to protect the swab that doctors insert into patients nostrils while it is transferred to a medical lab. In this case, the beer maker has already delivered 1,000 vials of the liquid to Californias Enloe Medical Center and is planning to make up to 10,000 more.

Back to index

Employees at Jacksonville, Florida-based third-party logistics service provider (3PL) Atlantic Logistics have started a bulk hand sanitizer rebottling program that will serve local truck drivers. In April, employees partnered with TravelCenters and TA-Petro to set up personal distribution of hand sanitizer and masks to drivers at their truck stop at I-10 and U.S. Highway 301 in Jacksonville.

Most Americans want to give back and say Thank you to the truckers that keep the shelves stocked and the country moving, Rob Hooper, Atlantic Logistics CEO, said in a statement. Im so proud of the initiative our employees took to help make these folks lives a little safer and simpler.

Back to index

Volunteers from the North American technology community have banded together to build a mobile app that helps truck drivers find essential services near their current locations, so they can continue operating safely during the Covid-19 pandemic.

Known as Truckers Welcome, the site serves as a social application that lets businesses add and share information about the services they are still able to provide to driverssuch as drive-through meals, washrooms, Wi-Fi, and fuel. With over 1,600 locations registered across the U.S. and Canada since it launched, the site addresses some of the significant challenges truck drivers face while on the road keeping goods and supplies flowing to grocery stores, hospitals, and communities, its creators say.

Back to index

Third-party logistics service provider (3PL) Logistics Plus Inc. provided free customs clearance and delivery services to transport a load of 50,000 surgical masks for the city of Erie, Pennsylvania.

The masks were originally donated by Eries sister city, Zibo, China, and airfreighted to Chicago. Erie-based Logistics Plus then facilitated the customs clearance and paperwork, took possession of the shipment, and arranged complimentary transportation of the goods from Chicago to Erie.

Together we are Erie Strong, Jim Berlin, founder and CEO of Logistics Plus, said in a release. Helping [Erie] Mayor [Joe] Schember and the city get these masks from Chicago to Erie and in the hands of our front-line government workers was an easy decision. It feels good to donate and to do something for those in need.

Back to index

The Raymond Corp. put its weight into the Covid-19 fight to help local health-care workers and first responders. The New York-based maker of forklifts and other material handling equipment and solutions used its engineering might to 3D print and assemble face shields at its Greene, New York, facility. Company President and CEO Mike Field said in April that Raymond would produce 2,000 face shields to be distributed to local hospitals and first responders.

Like everyone, we at Raymond have heard the appeals for protective equipment from our local health-care workers battling the Covid-19 pandemic, Field said in a release. Raymond has the ability and desire to utilize our vast production capabilities to support those crucial employees. ... We will continue to monitor the evolving situation to determine how best we can support our local health-care heroes.

Back to index

Supply chain technology and risk management firm Resilinc responded early to increased demand for critical health-care supplies by launching the The Exchange at Resilinc, an online clearinghouse designed to match available inventory with hospitals that need items, including personal protective equipment, to fight the Covid-19 pandemic. The company announced the initiative March 25, and the exchange was up and running by mid-April.

Resilinc partnered with representatives from the health-care and logistics sectors to create the exchange, which will allow group purchasing organizations (GPOs), distributors, and hospitals to connect and exchange inventory and to access donated inventory from manufacturers and other organizations. The program is designed to digitize and broaden a system that is largely done informally and manually between trading partners. The exchange will be free for all U.S. hospitals through September, according to Resilinc Founder and CEO Bindiya Vakil.

Back to index

The American Trucking Associations (ATA) joined with corporate partners to further its #thankatrucker campaign, launching its Providing for the Frontlines initiative in May.

Insurance provider OneBeacon, U.S. Bank, Michelin, and Hydro-Chem Systems are partnering with ATA to provide hand sanitizer nationwide as well as meals for professional truck drivers on the road, the groups said.

This new initiative aims to celebrate unsung heroes in the trucking industry who continue to bravely deliver Americas goods throughout the ongoing coronavirus pandemic, as well as provide relief to the hard-working men and women behind the wheel, Arlington, Virginia-based ATA said in a statement.

The initiative will include a photo contest in which drivers can submit a fun photo of themselves and their rig. Once submitted, they will be entered into a drawing to win a $25 electronic gift card for a meal of the drivers choice while on the road. Multiple winners will be selected daily. Truckers can enter and anyone can view the daily winners at http://www.trucking.org/thankatrucker.

Providing for the Frontlines builds on ATAs efforts to support truckers nationwide. Also in May, the association teamed up with Protective Insurance and ABF Freight to supply 550 gallons of hand sanitizer to eight states across the country. By mid-month, thousands of drivers had been able to refill their personal supply at no cost to them, ATA said.

Back to index

Logistics robot technology provider Brain Corp. is donating $1.6 million worth of autonomous floor-cleaning robots and services to essential businesses during the Covid-19 pandemic.

Autonomous mobile robots (AMRs) are playing a vital role in helping support essential businesses and their workers on the front lines of the health crisis, since retailers, airports, and hospitals are required to clean more frequently and deliver more cleaning coverage than usual. Autonomous floor scrubbers powered by Brain Corp.s BrainOS software are providing more than 8,000 hours of daily workequal to a quarter-million hours throughout the month of Maythat otherwise would have to be done by an essential worker, the company said.

Back to index

Transport and logistics firms Gebrder Weiss and Delta Group Logistics teamed up to deliver thousands of pieces of personal protective equipment (PPE) to health and safety workers in the Chicago area as they continued to fight the Covid-19 pandemic in May.

The companies purchased and distributed 8,000 face masks and 1,000 face shields to various organizations and companies in Chicago and the surrounding suburbs. A majority of the face shields donated went directly to Springfield, Illinois, to help stock the Centers for Medicare & Medicaid Services state surplus warehouse so that shields are ready when they are needed, the companies said.

The companies planned to continue donating PPE throughout the month.

Separately, Illinois-based Seko Logistics has stepped up its own PPE efforts with donations for front-line workers and by providing additional equipment for its own essential workforce, the company said.

As of mid-May, Seko Logistics had distributed more than 28,000 face masks and 138,000 gloves to its front-line teams in North America along with additional PPE kits for its MedTec drivers, which support medical deliveries nationwide. That comes on top of a pledge to donate $200,000 for the purchase of PPE for health-care workers treating Covid-19 patients around the country.

Back to index

Liquid and powder coatings supplier Axalta has shifted the manufacturing capabilities of its facility in Tlalnepantla, Mexico, to produce more than 1,000 liters (264 gallons) of hand sanitizer, which is being donated to local health-care facilities, first responders, and other essential businesses.

These efforts complement Axaltas global support of coronavirus relief efforts, which include sending personal protective equipment (PPE) to hospitals in the U.S., France, Belgium, and Germany, and providing more than 5,000 seat covers to medical professionals, who can use the seat covers in their own cars to reduce the risk of transmitting the coronavirus when they are visiting those infected with the virus.

Back to index

Aerospace and defense contractor Lockheed Martin Corp. has donated cargo capacity on its corporate aircraft as an in-kind donation to support the federal governments Covid-19 response for medical transplants, helping ensure that the life-saving products from European donors reach American patients on time.

The flights help ensure the timely delivery of bone marrow and blood stem cells for transplant, a need that arose when the National Marrow Donor Program (NMDP)/Be The Match ran out of available European Union couriers to deliver life-saving cells to U.S. patients, since tens of thousands of commercial flights had been canceled during the pandemic. Lockheed Martin will be providing weekly air transport based on government medical needflying government medical teams to the most critical, high-priority locations around the country and/or flying to support bone-marrow transport to help with the governments coronavirus response.

Back to index

Chocolate maker The Hershey Co. has committed $1 million to acquire, install, and staff a new manufacturing line dedicated to the production of face masks during the Covid-19 emergency.

Leveraging its internal engineering capabilities and its relationships with equipment manufacturer JR Automation and General Motors, which is making similar masks, the company is moving quickly to address the nationwide shortage of protective equipment. When it becomes operational, the Hershey, Pennsylvania-based line will be capable of producing up to 45,000 masks per day, the company said in mid-May.

Back to index

Transportation and logistics services provider DHL Global Forwarding, packaging and design venture Royal Bay, and tracking technology firm LocatorX have stepped up to provide personal protective equipment (PPE) and other services to front-line workers.

DHL Global Forwarding is partnering with customers in the health-care industry to ship more than 100 tons per week of medical supplies, equipment parts, pharmaceuticals, and protective clothing for hospitals, health-care workers, and patients throughout the United States and is also offering special charters to and from China to ease the capacity crunch for customers, officials said in May.

Royal Bay, a joint venture between packaging and design companies Bay Cities and The Royal Group, is assembling and packaging 2 million face shields for essential workers. The shields will be distributed to medical suppliers and distributors, who will send them to medical facilities and hospitals nationwide. At capacity, Royal Bay will assemble and package 500,000 units per week, the companies said.

Atlanta-based tracking technology firm LocatorX has launched a National Medical Device Registry allowing hospitals to log their life-saving equipment at no cost during the Covid-19 crisis. The registry will also help hospitals quickly and easily identify the status of venilators available for loan, the company said.

Read more:
Heroes of the Supply Chain | 2020-06-25 - DC Velocity

The frenetic search for the miracle that will rid the world of COVID-19 is branching out in a thousand directions, and a large part of the microbial treasure hunt is going on in the Bay Area, where major progress has been made in the 100 days since residents were ordered to shelter in place.

Scientists at universities, laboratories, biotechnology companies and drug manufacturers are combing through blood plasma taken from infected patients for secrets that will help them fight the disease.

The key is likely a super-strength antibody found in some patients. But researchers must first figure out how those antibodies work and how they can be harnessed and used to stop the many health problems associated with COVID-19, particularly acute respiratory distress syndrome, or ARDS, which has killed more people than any other complication connected to the disease.

Other developments showing promise include injections of mesenchymal stem cells, found in bone marrow and umbilical cords, that doctors are studying to battle inflammation caused by ARDS. And a steroid called dexamethasone reduced the number of deaths by halting the overreactive immune responses in seriously ill patients in the United Kingdom.

In all, more than 130 vaccines and 220 treatments are being tested worldwide.

What follows is a list of some of the most promising elixirs, medications and vaccines with ties to the Bay Area:

Monoclonal antibodies / Vir Biotechnology, San Francisco: Scientists at Vir and several institutions, including Stanford and UCSF, are studying monoclonal antibodies, which are clones of coronavirus-fighting antibodies produced by COVID-19 patients.

The idea is to utilize these neutralizing antibodies which bind to the virus crown-like spikes and prevent them from entering and hijacking human cells.

Only about 5% of coronavirus patients have these super-strength antibodies, and those people are believed to be immune to a second attack.

The trick for scientists at Vir is to identify these neutralizing antibodies, harvest, purify and clone them. If they succeed, the resulting monoclones could then be used to inoculate people and it is hoped give them long-term immunity against the coronavirus. The company recently signed a deal with Samsung Biologics, in South Korea, to scale up production of a temporary vaccine in the fall after clinical trials are complete.

Another monoclonal antibody, leronlimab, is being studied in coronavirus clinical trials by its Washington state drugmaker, CytoDyn. The companys chief medical officer is in San Francisco, and the company that does laboratory tests of leronlimab is in San Carlos.

Interferon-lambda / Stanford University: Doctors at Stanford are running a trial to see if interferon-lambda, which is administered by injection, helps patients in the early stages of COVID-19. Interferon-lambda is a manufactured version of a naturally occurring protein that has been used to treat hepatitis. Stanford doctors hope it will boost the immune system response to coronavirus infections.

Dr. Upinder Singh, a Stanford infectious-disease expert, said the trial has enrolled more than 50 patients and is halfway finished. We have noted that patients tolerate the drug very well, she said.

Mesenchymal stem cells / UCSF and UC Davis Medical Center: UCSF Dr. Michael Matthay is leading a study about whether a kind of stem cell found in bone marrow can help patients with ARDS. Matthay hopes that the stem cells can help reduce the inflammation associated with some of ARDS most dire respiratory symptoms, and help patients lungs to recover.

Matthay is aiming to enroll 120 patients in San Francisco, the UC Davis Medical Center in Sacramento and hospitals in a handful of other states. He said the trial, which includes a small number ARDS patients who dont have COVID-19, should have results within a year. So far 17 patients are enrolled in the trial, most of them in San Francisco.

Remdesivir / Gilead Sciences (Foster City): Remdesivir, once conceived as a potential treatment for ebola, was the first drug to show some promise in treating COVID-19 patients. The drug interferes with the process through which the virus replicates itself. A large study led by the federal government generated excitement in late April when officials said hospitalized patients who received remdesivir intravenously recovered faster than those who received a placebo.

A later study looking at dosage showed some benefit for moderately ill COVID-19 patients who received remdesivir for five days, but improvement among those who got it for 10 days was not statistically significant. Gilead, a drug company, recently announced that it will soon launch another clinical trial to see how remdesivir works on 50 pediatric patients, from newborns to teenagers, with moderate to severe COVID-19 symptoms. More than 30 locations in the U.S. and Europe will be involved in the trial, the company said.

Coronavirus crisis: 100 days

Editors note: Its been 100 days since the Bay Area sheltered in place, protecting itself from the coronavirus pandemic. What have we learned in that time? And what does the future hold for the region and its fight against COVID-19? The Chronicle explores the past 100 days and looks to the future in this exclusive report.

Favipiravir / Fujifilm Toyama Chemical (Stanford University): This antiviral drug, developed in 2014 by a subsidiary of the Japanese film company to treat influenza, is undergoing numerous clinical studies worldwide, including a Stanford University trial that began this month. Unlike remdesivir, it can be administered orally, so it can be used to treat patients early in the disease, before hospitalization is necessary.

Stanford epidemiologists want to see if favipiravir, which has shown promising results in other trials, prevents the coronavirus from replicating in human cells, halts the shedding of the virus and reduces the severity of infection. The Stanford study, the only outpatient trial for this drug in the nation, is enrolling 120 people who have been diagnosed with COVID-19 within the past 72 hours. Half of them will get a placebo. People can enroll by emailing treatcovid@stanford.edu.

Colchicine / UCSF (San Francisco and New York): The anti-inflammatory drug commonly used to treat gout flare-ups is being studied in the U.S. by scientists at UCSF and New York University. The drug short-circuits inflammation by decreasing the bodys production of certain proteins, and researchers hope that it will reduce lung complications and prevent deaths from COVID-19. About 6,000 patients are receiving colchicine or a placebo during the clinical trial, dubbed Colcorona, which began in March and is expected to be completed in September.

Selinexor / Kaiser Permanente: Kaiser hospitals in San Francisco, Oakland and Sacramento are studying selinexor, an anticancer drug that blocks a key protein in the cellular machinery for DNA processing, as a potential COVID-19 treatment. The drug has both antiviral and anti-inflammatory properties, and its administered orally, according to Kaisers Dr. Jacek Skarbinski. The trial aims to enroll 250 patients with severe symptoms at Kaiser and other hospitals that are participating nationwide.

VXA-COV2-1 / Vaxart, South San Francisco: The biotechnology company Vaxart is testing this drug to see if it is as effective at controlling COVID-19 as trials have shown it to be against influenza. VXA-COV2-1, the only potential vaccine in pill form, uses the genetic code of the coronavirus to trigger a defensive response in mucous membranes. The hope is that the newly fortified membranes will prevent the virus from entering the body.

Its the only vaccine (candidate) that activates the first line of defense, which is the mucosa, said Andrei Floroiu, Vaxarts chief executive, noting that intravenous vaccines kill the virus after it is inside the body. Our vaccine may prevent you from getting infected at all.

The drug was effective against influenza and norovirus in trials and appears to work on laboratory animals, Floroiu said. He expects trials of VXA-COV2-1 on humans to begin later this summer.

VaxiPatch / Verndari (Napa and UC Davis Medical Center): Napa vaccine company Verndari makes a patented adhesive patch that can deliver a vaccine instead of a shot. Now, the company is trying to make a vaccine for COVID-19 that they can administer through that patch. At UC Davis Medical Center in Sacramento, Verndari researchers are developing a potential vaccine that relies on the coronavirus spike-shaped protein. When injected into a person, the substance would ideally train their body to recognize the virus and fight it off without becoming ill.

A spokeswoman told The Chronicle that the companys preclinical tests have shown early, positive data in developing an immune response. Verndari hopes to move into the next phase of testing in the coming weeks and start clinical trials in humans this year.

If the vaccine is proved effective and safe, patients could receive it through the mail, according to company CEO Dr. Daniel Henderson. The patch would leave a temporary mark on the skin that patients could photograph and send to their doctor as proof they have taken the vaccine, Henderson has said.

Peter Fimrite and J.D. Morris are San Francisco Chronicle staff writers. Email: pfimrite@sfchronicle.com, jd.morris@sfchronicle.com Twitter: @pfimrite, @thejdmorris

Go here to read the rest:
Efforts at coronavirus vaccines and treatments abound in the Bay Area - San Francisco Chronicle

The Cell Therapy Manufacturing Market Research Report 2020 published by Prophecy Market Insights is an all-inclusive business research study on the current state of the industry which analyzes innovative strategies for business growth and describes significant factors such as top developers/manufacturers, production value, key regions, and growth rate. Impact of Covid-19 pandemic on the market will be completely analyzed in this report and it will also quantify the impact of this pandemic on the market.

The research study encompasses an evaluation of the market, including growth rate, current scenario, and volume inflation prospects, based on DROT and Porters Five Forces analyses. The market study pitches light on the various factors that are projected to impact the overall market dynamics of the Cell Therapy Manufacturing market over the forecast period (2019-2029).

Regional Overview:

The survey report includes a vast investigation of the geographical scene of the Cell Therapy Manufacturing market, which is manifestly arranged into the localities. The report provides an analysis of regional market players operating in the specific market and outcomes related to the target market for more than 20 countries.

Australia, New Zealand, Rest of Asia-Pacific

The facts and data are represented in the Cell Therapy Manufacturing report using graphs, pie charts, tables, figures and graphical representations helping analyze worldwide key trends & statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/21

The research report also focuses on global major leading industry players of Cell Therapy Manufacturing market report providing information such as company profiles, product picture and specification, R&D developments, distribution & production capacity, distribution channels, price, cost, revenue and contact information. The research report examines, legal policies, and competitive analysis between the leading and emerging and upcoming market trends.

Cell Therapy ManufacturingMarket Key Companies:

harmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec.

The predictions mentioned in the Cell Therapy Manufacturing market report have been derived using proven research techniques, assumptions and methodologies. This market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry.

Segmentation Overview:

The report provides an in-depth analysis of the Cell Therapy Manufacturing market segments and highlights the latest trending segment and major innovations in the market. In addition to this, it states the impact of these segments on the growth of the market. Apart from key players analysis provoking business-related decisions that are usually backed by prevalent market conditions, we also do substantial analysis of market based on COVID-19 impact, detailed analysis on economic, health and financial structure.

Request Discount @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/21

Key Questions Answered in Report:

Stakeholders Benefit:

Get In-depth TOC @ https://www.prophecymarketinsights.com/market_insight/Global-Cell-Therapy-Manufacturing-Market-21

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

VISIT MY BLOG:- https://medium.com/@varshashirode0000/global-blockchain-in-genomics-market-trends-analysis-and-forecast-till-2029-3f92b8bdc622

Continued here:
Cell Therapy Manufacturing Market: Opportunities Forecast and Value Chain 2020-2030 - 3rd Watch News

Amir Hashemi,1 Masoumeh Ezati,2 Javad Mohammadnejad,3 Behzad Houshmand,4 Shahab Faghihi5

1Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran 14395-1561, Iran; 2Tissue Engineering and Biomaterials Research Center, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran 14965/161, Iran; 3Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran 14395-1561, Iran; 4Department of Periodontics, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran 19857-17443, Iran; 5Tissue Engineering and Biomaterials Research Center, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran 14965/161, Iran

Correspondence: Javad Mohammadnejad; Shahab Faghihi Tel +9821 8609-3078Tel/ Fax +98 21 44787386Fax +98(21)88497324Email mohamadnejad@ut.ac.ir; sfaghihi@nigeb.ac.ir

Background: Ineffective integration has been recognized as one of the major causes of early orthopedic failure of titanium-based implants. One strategy to address this problem is to develop modified titanium surfaces that promote osteoblast differentiation. This study explored titanium surfaces modified with TiO2 nanotubes (TiO2 NTs) capable of localized drug delivery into bone and enhanced osteoblast cell differentiation.Materials and Methods: Briefly, TiO2 NTs were subjected to anodic oxidation and loaded with Metformin, a widely used diabetes drug. To create surfaces with sustainable drug-eluting characteristics, TiO2 NTs were spin coated with a thin layer of chitosan. The surfaces were characterized via scanning electron microscopy, atomic force microscopy, and contact angle measurements. The surfaces were then exposed to mesenchymal bone marrow stem cells (MSCs) to evaluate cell adhesion, growth, differentiation, and morphology on the modified surfaces.Results: A noticeable increase in drug release time (3 days vs 20 days) and a decrease in burst release characteristics (85% to 7%) was observed in coated samples as compared to uncoated samples, respectively. Chitosan-coated TiO2 NTs exhibited a considerable enhancement in cell adhesion, proliferation, and genetic expression of type I collagen, and alkaline phosphatase activity as compared to uncoated TiO2 NTs.Conclusion: TiO2 NT surfaces with a chitosan coating are capable of delivering Metformin to a bone site over a sustained period of time with the potential to enhance MSCs cell attachment, proliferation, and differentiation.

Keywords: titania nanotubes, titanium, osteogenic differentiation, anodization, mesenchymal bone marrow stem cells, MSCs

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

More:
Chitosan Coating of TiO2 Nanotube Arrays for Improved Metformin Releas | IJN - Dove Medical Press

2020 World Sickle Cell Day: Symptoms of sickle cell can appear around 5 months of age

World Sickle Cell Day is observed on June 19. The day is meant to raise awareness about sickle cell disease, which is a group of disorders that affect haemoglobin, the molecule in red blood cells which deliver oxygen to cells throughout the body. People with this disorder have haemoglobin S, an atypical haemoglobin molecule which can distort red blood cells into a sickle or a crescent shape. This disease is a blood disorder which is inherited and passed down from parents to the child. In 2008, the UN General Assembly recognised sickle cell disease as a public health problem, and one of the world's foremost genetic diseases.

Symptoms of sickle cell disease usually appear around five months of age. The symptoms vary from person to person and change over time.

Symptoms of sickle cell disease can appear from two to five months of age. But in milder cases, the symptoms may appear till teenage.

Sickle cell disease can cause vision problemsPhoto Credit: iStock

Also read:These Iron-Packed Foods Can Combat Anemia And Other Health Problems

One can get infected with sickle cell disease if both parents have the problem gene and pass it on to their child.

1. HbSS or sickle cell anemia is a severe kind of sickle cell disease. It occurs when child inherits sickle cell gene from each parent.

2. HbSc occurs when one parents has sickle cell gene and the other has a gene from abnormal haemoglobin.

3. Hbs beta thalassemia occurs when sickle cell gene is passed from one parent, and beta-thalassemia is passed on from the other.

If only one parent has the problem gene, then the child will not have symptoms but will have the gene known as sickle cell trait.

Also read:Anemia During Pregnancy: Symptoms, Risk Factors And Prevention Steps Every Woman Must Know

Sickle cell can be detected in an infant during newborn screening process. In case of family history, it can be detected during pregnancy.

Bone marrow or stem cell transplant is the only permanent cure for sickle cell disease. Early detection and timely treatment can help in managing symptoms, offer relief from pain and prevent severe complications.

Apart from stem cell transplant, the symptoms can be managed with the help of periodic blood transfusion, pain killers, vaccinations and antibiotics.

Also read:6 Side-Effects Of Overuse Of Antibiotics And Home Remedies By Rujuta Diwekar That Can Be As Effective

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

Follow this link:
World Sickle Cell Day 2020: Know The Types, Symptoms, Causes And Treatment - NDTV

The global Rheumatoid Arthritis Stem Cell Therapy market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Rheumatoid Arthritis Stem Cell Therapy market player in a comprehensive way. Further, the Rheumatoid Arthritis Stem Cell Therapy market report emphasizes the adoption pattern of the Rheumatoid Arthritis Stem Cell Therapy across various industries.Request Sample Reporthttps://www.factmr.com/connectus/sample?flag=S&rep_id=1001The Rheumatoid Arthritis Stem Cell Therapy market report highlights the following players:The global market for rheumatoid arthritis stem cell therapy is highly fragmented. Examples of some of the key players operating in the global rheumatoid arthritis stem cell therapy market include Mesoblast Ltd., Roslin Cells, Regeneus Ltd, ReNeuron Group plc, International Stem Cell Corporation, TiGenix and others.

The Rheumatoid Arthritis Stem Cell Therapy market report examines the operating pattern of each player new product launches, partnerships, and acquisitions has been examined in detail.Important regions covered in the Rheumatoid Arthritis Stem Cell Therapy market report include:

North America (U.S., Canada)Latin America (Mexico, Brazil)Western Europe (Germany, Italy, U.K., Spain, France, Nordic countries, BENELUX)Eastern Europe (Russia, Poland, Rest Of Eastern Europe)Asia Pacific Excluding Japan (China, India, Australia & New Zealand)JapanMiddle East and Africa (GCC, S. Africa, Rest Of MEA)

The Rheumatoid Arthritis Stem Cell Therapy market report takes into consideration the following segments by treatment type:

Allogeneic Mesenchymal stem cellsBone marrow TransplantAdipose Tissue Stem Cells

The Rheumatoid Arthritis Stem Cell Therapy market report contain the following distribution channel:

HospitalsAmbulatory Surgical CentersSpecialty ClinicsHave Any Query? Ask our Industry Experts-https://www.factmr.com/connectus/sample?flag=AE&rep_id=1001

Buy the report at a discounted rate!!! Exclusive offer!!!

The Rheumatoid Arthritis Stem Cell Therapy market report offers a plethora of insights which include:

Changing consumption pattern among individuals globally.Historical and future progress of the global Rheumatoid Arthritis Stem Cell Therapy market.Region-wise and country-wise segmentation of the Rheumatoid Arthritis Stem Cell Therapy market to understand the revenue, and growth lookout in these areas.Accurate Year-on-Year growth of the global Rheumatoid Arthritis Stem Cell Therapy market.Important trends, including proprietary technologies, ecological conservation, and globalization affecting the global Rheumatoid Arthritis Stem Cell Therapy market.

The Rheumatoid Arthritis Stem Cell Therapy market report answers important questions which include:

Which regulatory authorities have granted approval to the application of Rheumatoid Arthritis Stem Cell Therapy in Health industry?How will the global Rheumatoid Arthritis Stem Cell Therapy market grow over the forecast period?Which end use industry is set to become the leading consumer of Rheumatoid Arthritis Stem Cell Therapy by 2028?What manufacturing techniques are involved in the production of the Rheumatoid Arthritis Stem Cell Therapy?Which regions are the Rheumatoid Arthritis Stem Cell Therapy market players targeting to channelize their production portfolio?Get Full Access of the Report @https://www.factmr.com/report/1001/rheumatoid-arthritis-stem-cell-therapy-market

Pertinent aspects this study on the Rheumatoid Arthritis Stem Cell Therapy market tries to answer exhaustively are:

What is the forecast size (revenue/volumes) of the most lucrative regional market? What is the share of the dominant product/technology segment in the Rheumatoid Arthritis Stem Cell Therapy market? What regions are likely to witness sizable investments in research and development funding? What are Covid 19 implication on Rheumatoid Arthritis Stem Cell Therapy market and learn how businesses can respond, manage and mitigate the risks? Which countries will be the next destination for industry leaders in order to tap new revenue streams? Which new regulations might cause disruption in industry sentiments in near future? Which is the share of the dominant end user? Which region is expected to rise at the most dominant growth rate? Which technologies will have massive impact of new avenues in the Rheumatoid Arthritis Stem Cell Therapy market? Which key end-use industry trends are expected to shape the growth prospects of the Rheumatoid Arthritis Stem Cell Therapy market? What factors will promote new entrants in the Rheumatoid Arthritis Stem Cell Therapy market? What is the degree of fragmentation in the Rheumatoid Arthritis Stem Cell Therapy market, and will it increase in coming years?Why Choose Fact.MR?

Fact.MR follows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

View post:
Rheumatoid Arthritis Stem Cell Therapy Market Future Innovation Strategies, Growth & Profit Analysis, Forecast by 2028 - The Cloud Tribune

Bone marrow transplants can save patients lives by essentially giving them a new immune system to fight off cancer. But they can also cause life-threatening side effects, so their use is relegated to the sickest of patients. Orca Bio wants to change that by taking aim at how these treatments are made.

The Bay Area biotech is coming out of stealth with a $192 million series D round that will propel a pipeline of high precision allogeneic cell therapies and the manufacturing technology behind those treatments. Founded in 2016, Orca Bio zeroed in on manufacturing to make bone marrow transplants safer and more effective.

Theres a bit of a trade-off: You can have precision and a few cells, or you can have lots of cells and sacrifice precision, Orca CEO and co-founder Ivan Dimov, Ph.D., told Fierce Biotech. Most folks out there deal with less precision in order to get the sheer number of cells to treat patients We focused on technology to process extremely large numbers of cells while still having single-cell precision.

White Paper: Keep Your GI Trials Moving During COVID-19

Clinical Inks intimate knowledge of and experience with GI trials enables a better deployment experience and improved trial conduct. Learn how our GI-specific data capture solutions can support virtual and hybrid trials during COVID-19.

RELATED: AACR: A look at next-gen CAR-T therapies for blood cancers

Orcas proposition is to take donor T cells and stem cells, sort them into their different subtypes and combine them in the right mixture to treat disease.

We dont genetically modify them. But if we now take these cells and build a proprietary mix of them with single-cell precision, we can define the function of what theyre going to do, Dimov said. We can elicit powerful curative effects and control toxicities in a precise way to enhance safety and efficacy in patients that essentially need a whole new blood and immune system.

Dimov likens the processto assembling different kinds of soldiers into the right army unit to give patients so they have a new immune system to seek and destroy cancers while not seeking and destroying the patient themselves and their own tissue.

Because the manufacturing process is quick and uses donor cells, Orcas treatments could eventually reach more patients than CAR-T therapies and other engineered cell therapies can. Some cancer patients may not have enough T cells, or T cells of good enough quality, to turn into a treatment, while others simply do not live long enough for the treatment to be made.

RELATED: BIO: Meet Refuge Biotech, the company developing 'intelligent' cell therapies

The series D, drawn from Lightspeed Ventures, 8VC, DCVC Bio, ND Capital, Mubadala investment Company, Kaiser Foundation Hospitals, Kaiser Permanente Group Trust and IMRF, brings Orcas total raised to nearly $300 million. That haulwill bring its lead program, TRGFT-201, through clinical development. The program is in a phase 1/2 study in patients with blood cancers, while a second program, OGFT-001, is in a phase 1 study, also in blood cancers.

Orcas first two programs are designed for patients with terminal blood cancers, but they could move earlier in the cancer care timeline if they prove to be safer than traditional bone marrow transplants. Beyond cancer, the approach could be applied to a range of genetic disorders of the blood and immune system. The companyhasnt decided where to go next, but Dimov said the approach could be useful in treating autoimmune diseases like Crohns disease or Type 1 diabetes.

Read the original post:
Orca Bio breaches the surface with $192M for 'high precision' cell therapies - FierceBiotech

PNH and aHUS, both are extremely rare and genetic diseases. Due to PNH, destruction of red blood cells of a person occurs quite sooner than it should. It is an acquired hematopoietic stem cell disorder. Hematopoietic stem cells are developed in bone marrow and eventually turn into red blood cells, white blood cells and platelets.

The Global PNH and aHUS Market study focuses major leading industry players with information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. It provides information on trends and developments, and focuses on markets and materials, capacities and technologies, and on the changing structure.

Our analysis involves the study of the market taking into consideration the impact of the COVID-19 pandemic. Please get in touch with us to get your hands on an exhaustive coverage of the impact of the current situation on the market. Our expert team of analysts will provide as per report customized to your requirement.

Request a sample of this premium research @: https://www.bigmarketresearch.com/request-sample/3871686?utm_source=RK&utm_medium=MDI

Top Key Players are covered in this report: Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Omeros Corporation

The report offers an exhaustive geographical analysis of the Global PNH and aHUS Market, covering important regions Such as: North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The Global PNH and aHUS Market is gaining pace and businesses have started understanding the benefits of analytics in the present day highly dynamic business environment. The market has witnessed several important developments over the past few years, with mounting volumes of business data and the shift from traditional data analysis platforms to self-service business analytics being some of the most prominent ones.

Microeconomic and macroeconomic factors which affect the PNH and aHUS Market and its growth, both positive and negative are also studied. The report features the impact of these factors on the ongoing market throughout the mentioned forecast period. The upcoming changing trends, factors driving as well as restricting the growth of the market are mentioned.

Segment by Type

Segment by Application

For the future period, sound forecasts on market value and volume are offered for each type and application. In the same period, the report also provides a detailed analysis of market value and consumption for each region. These insights are helpful in devising strategies for the future and take necessary steps. New project investment feasibility analysis and SWOT analysis are offered along with insights on industry barriers. Research findings and conclusions are mentioned at the end.

Reasons for Buying This Report:

-It Provides A Forward-Looking Perspective on Different Factors Driving or Restraining Market Growth.

-It Provides A Five-Year Forecast Assessed on The Basis of How the Market Is Predicted to Grow.

-It Helps in Understanding the Key Product Segments and Their Future.

-It Provides Pin Point Analysis of Changing Competition Dynamics and Keeps You Ahead of Competitors.

-It Helps in Making Informed Business Decisions by Having Complete Insights of Market and By Making an In-Depth Analysis of Market Segments.

Request a discount on standard prices of this premium research @: https://www.bigmarketresearch.com/request-for-discount/3871686?utm_source=RK&utm_medium=MDI

About Us:

Big Market Research has a range of research reports from various publishers across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.

We are instrumental in providing quantitative and qualitative insights on your area of interest by bringing reports from various publishers at one place to save your time and money. A lot of organizations across the world are gaining profits and great benefits from information gained through reports sourced by us.

Contact us:

Mr. Abhishek Paliwal

5933 NE Win Sivers Drive, #205, Portland,

OR 97220 United States

Direct: +1-971-202-1575

Toll Free: +1-800-910-6452

E-mail: [emailprotected]

Read more:
PNH and aHUS Market with Key Findings, Regional Analysis, Key Players Profiles, Current Trends, Business Development and Upcoming Prospects 2020-2026...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA) and Beam Therapeutics (Nasdaq: BEAM) today announced a non-exclusive research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magentas novel targeted ADC for conditioning of patients with sickle cell disease and beta-thalassemia receiving Beams base editing therapies. Beam is pursuing two differentiated base editing approaches to treat hemoglobinopathies: its hereditary persistence of fetal hemoglobin (HPFH) program to precisely and robustly elevate fetal hemoglobin, which could be used in treatments for both sickle cell disease and beta-thalassemia, as well as a novel approach to directly correct the sickle causing point mutation (Makassar).

Conditioning is a critical component necessary to prepare a patients body to receive the edited cells, which carry the corrected gene and must engraft in the patients bone marrow in order to be effective. Todays conditioning regimens rely on nonspecific chemotherapy or radiation, which are associated with significant toxicities. MGTA-117 precisely targets only hematopoietic stem and progenitor cells, sparing immune cells, and has shown high selectivity, potent efficacy, wide safety margins and broad tolerability in non-human primate models. MGTA-117 may be capable of clearing space in bone marrow to support long-term engraftment and rapid recovery in patients.

Beam has demonstrated the ability to edit individual DNA bases in hematopoietic stem cells at high efficiency and with little impact on the viability of edited cells relative to unedited cells using its novel base editing technology. Combining MGTA-117 with Beams HPFH and Makassar base editors could meaningfully advance the treatment of patients with sickle cell disease or beta-thalassemia.

We believe patients will benefit from a more precise process to remove hematopoietic stem cells and prepare them to receive genetic medicines. Magenta has developed targeted ADCs as the preferred modality for our conditioning programs, and we have designed MGTA-117 specifically to optimize it for use with a genetically-modified cell product delivered in a transplant setting, said Jason Gardner, D.Phil., president and chief executive officer, Magenta Therapeutics. Beams next-generation base editing technology complements our next-generation conditioning approach very well, and we are excited to combine these strengths to address the still-significant unmet medical needs of the sickle cell and beta-thalassemia patient communities.

Base editing has the potential to offer lifelong treatment for patients with many diseases, including sickle cell disease and beta-thalassemia. Our novel base editors create precise single base changes in genes without cutting the DNA, enabling durable correction of hematopoietic stem cells with minimal effects on cell viability or genomic integrity, said John Evans, chief executive officer of Beam. Combining the precision of our base editing technology with the more targeted conditioning regimen enabled by MGTA-117 could further improve therapeutic outcomes for patients suffering from these severe diseases. We look forward to partnering with the Magenta team to explore these novel technologies together.

Beam will be responsible for clinical trial costs related to development of Beams base editors when combined with MGTA-117, while Magenta will continue to be responsible for all other development costs of MGTA-117. Magenta will also continue to develop MGTA-117 in other diseases, including blood cancers and genetic diseases. Each company will retain all commercial rights to their respective technologies.

About MGTA-117

MGTA-117, Magentas most advanced conditioning program, is a CD117-targeted antibody engineered for the transplant setting and conjugated to amanitin, a toxin in-licensed from Heidelberg Pharma. It is designed to precisely deplete only hematopoietic stem and progenitor cells and has shown high selectivity, potent efficacy, wide safety margins and broad tolerability in non-human primate models, suggesting that it may be capable of clearing space in bone marrow to support long-term engraftment and rapid recovery in patients. Magenta plans to complete IND-enabling studies this year and initiate clinical studies in 2021. Magenta will continue to develop MGTA-117 in other diseases, including blood cancers and genetic diseases.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with autoimmune diseases, genetic diseases and blood cancers. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients. Magenta is based in Cambridge, Mass. For more information, please visit http://www.magentatx.com. Follow Magenta on Twitter: @magentatx.

About Base Editing and Beam TherapeuticsBeam Therapeutics (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines through the use of base editing. Beams proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization focused on its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. For more information, visit http://www.Beamtx.com.

Magenta Therapeutics Forward-Looking StatementsThis press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including, without limitation, statements regarding the research and clinical collaboration agreement between Magenta and Beam, including the timing, progress and success of the collaboration contemplated under the agreement, the successful evaluation of MGTA-117 in conjunction with Beams base-editing therapies under the agreement, the anticipated cost allocation and other commercial terms under the agreement, Magentas strategy and business plan, the future development, manufacture and commercialization between Beam and Magenta as well as statements regarding expectations and plans for the anticipated timing of Magentas clinical trials and regulatory filings and the development of Magentas product candidates and advancement of Magentas preclinical programs. The use of words such as may, will, could, should, expects, intends, plans, anticipates, believes, estimates, predicts, projects, seeks, endeavor, potential, continue or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation, risks set forth under the caption Risk Factors in Magentas most recent Annual Report on Form 10-K filed on March 3, 2020, as updated by Magentas most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission, risks, uncertainties and assumptions regarding the impact of the COVID-19 pandemic to Magentas business, operations, strategy, goals and anticipated timelines, and risks, uncertainties and assumptions inherent in preclinical and clinical studies, including, without limitation, whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials and the expected timing of submissions for regulatory approval or review by governmental authorities. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Beam Forward-Looking Statements

This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the timing, progress and success of the collaboration contemplated under the agreement between Beam and Magenta, the successful evaluation of MGTA-117 in conjunction with Beams base-editing therapies under the agreement, the expected timing of filing INDs applications and the therapeutic applications of Beams technology. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks and uncertainties, among other things, regarding: the success in development and potential commercialization of our product candidates; Beams ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; whether preclinical testing of our product candidates and preliminary or interim data from preclinical and clinical trials will be predictive of the results or success of ongoing or later clinical trials; that enrollment of clinical trials may take longer than expected; that Beams product candidates will experience manufacturing or supply interruptions or failures; that Beam will be unable to successfully initiate or complete the preclinical and clinical development and eventual commercialization of product candidates; that the development and commercialization of Beams product candidates will take longer or cost more than planned; the impact of COVID-19 on Beams business and the other risks and uncertainties identified under the heading Risk Factors and in Beams Annual Reports on Form 10-K for the year ended December 31, 2019 and in Beams Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release. Factors or events that could cause Beams actual results to differ may emerge from time to time, and it is not possible for Beam to predict all of them. Beam undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

See the article here:
Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen...

PUBLISHED: 18:00 18 June 2020

Simon Parkin

Imogen Roe returned home to Norfolk after 100 days in isolation in hospital. Picture: Anna Dagless

Archant

A nine-year-old girls life was saved by an anonymous blood stem cell donor after a brave battle with leukaemia in which she asked her mum am I going to die?

Email this article to a friend

To send a link to this page you must be logged in.

Imogen Roe, from Norwich, had just turned six when she was treated for routine tonsillitis. But her worried parents, Anna and Dean, took her back to the doctors when they noticed abnormal bruising and a rash on her body.

They were told to take Imogen to their local hospital, and were soon confronted with the devastating diagnosis.

Mum Anna, 38, said: We suspected it was a reaction to penicillin at worst. But within an hour of being at our local hospital we were told it was leukaemia, and within 24 hours we were in Addenbrookes Hospital. It all happened so fast, I dont remember feeling much other than panic and shock.

Because of the aggressiveness of her leukaemia, young Imogen began two-and-a-half years of high dosage chemotherapy.

Anna said: Imogen was such a trouper, and very co-operative which made for a very easy patient!

I cannot believe how well she just got on with things; cannulas, nose tubes, general anaesthetics, surgery - even though at times she has been very scared about procedures.

During this time the family was divided, with Imogen and her mum in Addenbrookes, whilst Dad Dean, 39, stayed at home with their other two children, Imogens twin sister Charlotte, and older brother Liam, 11.

MORE: Esm, three, wins 19-month cancer battle but cannot celebrate traditional bell ringingIn January 2019, almost three years after her diagnosis, young Imogen finished her chemo and rang her end of treatment bell to huge applause from doctors, nurses, hospital staff - and her proud, but exhausted parents.

The young family were finally able to get their lives back on track, but unfortunately more heartbreaking news was just around the corner.

Anna said: It was July 2019, almost three years to the day since Imogens original diagnosis, and we had just bought a puppy and booked a family holiday abroad with friends. Then we noticed that familiar rash on her legs, and were told to bring her to hospital.

After undergoing tests, doctors confirmed the worst Imogen had relapsed and the leukaemia had come back.

Doctors revealed that, in addition to further chemotherapy, Imogens best chance of beating the disease was to have a blood stem cell transplant from a matching donor.

Imogens siblings were both tested, and the family were delighted to be told that her sister Charlotte was a 100% match.

However, after further tests, they were confronted with shocking news after a decade of thinking Charlotte and Imogen were non-identical twins, they were in fact identical, which meant that Charlotte would not be a suitable donor after all.

Doctors began looking for Imogens potential lifesaver elsewhere searching the worldwide register of potential blood stem cell donors, hoping to find a perfect stranger who happens to be Imogens genetic twin.

With Imogens life hanging in the balance a match was found. Cord blood, donated by a new mother in the USA and frozen nine years prior, was a perfect match for Imogen. This was the only suitable match for Imogen anywhere in the world.

MORE: How support, prayers and herbal rememdies helped nurse beat coronavirusAs the frozen cord blood was prepared to be flown from America to the UK, Imogen had 10 days of conditioning treatment prior to transplant; four days of extremely strong chemotherapy, and then eight sessions of total body irradiation, to prepare her to receive the new blood stem cells.

This is an incredibly vulnerable point in any treatment plan. The new marrow should, over a few weeks, start to regenerate within the body, but for Imogen, after 36 days of daily blood tests, there was still no sign of any new cells being manufactured.

Her mum said: It was a very serious situation as without any white cells to fight off infection, Imogen was extremely vulnerable even from her isolation room, as you can pick up bugs from your own body.

Ten days post transplant she got an infection, and she went into septic shock. This led to several serious viruses, a chest infection, and bacterial infection. We had the rapid response team on standby for a transfer to intensive care, but Imogen pulled through, just as her dad arrived after making the five hour journey from our home.

Imogen remained in isolation in Bristol for 99 days, fighting off multiple infections, whilst dad Dean travelled the five hours back and forth between home and the hospital to bring Anna clean clothes and supplies.

Finally, Imogen was transferred back to Addenbrookes to continue her recovery one step closer to home.

MORE: Wife of rugby star launches new business two years after being given a month to liveOn March 13, in the midst of the Covid-19 pandemic, she was finally discharged and returned home to her mum, dad and siblings, who are now all self isolating.

It had been 170 days since she, or mum Anna, had seen any extended family.

Speaking about Imogens anonymous donor, Anna said the family were acutely aware of the luck involved in finding a match.

She said: Imogen had just one match. There are some people we know through our time in hospitals who were fortunate enough to have a selection of matches, and many others are still waiting for a match that may never come.

If you are aged between 17 and 55 and in general good health, you take the first step to register as a blood stem cell donor by registering for a home swab kit at dkms.org.uk

If you value what this story gives you, please consider supporting the Eastern Daily Press. Click the link in the yellow box below for details.

See the article here:
Anonymous US stem cell donor saves the life of Norwich girl - Eastern Daily Press

Global Bone Marrow-Derived Stem Cells (BMSCS) Market research report delivers comprehensive analysis of the market structure along with estimations of the various segments and sub-segments of the market. This study also analyzes the market status, market share, growth rate, sales volume, future trends, market drivers, market restraints, revenue generation, opportunities and challenges, risks and entry barriers, sales channels, and distributors. The company profiles of all the chief and dominating market players and brands who are taking steps such as product launches, joint ventures, mergers and acquisitions are mentioned in the report. With the use of SWOT analysis and Porters Five Forces analysis which are two of the standard, prominent and full-proof methods, this Global Bone Marrow-Derived Stem Cells (BMSCS) Market report is been framed.

Global Bone Marrow-Derived Stem Cells (BMSCS) Market By Service Type (Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation), Application (Personalized Banking Applications, Research Applications, Clinical Applications), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027

By providing an absolute overview of the market, Global Bone Marrow-Derived Stem Cells (BMSCS) Market report covers various aspects of market analysis, product definition, market segmentation, key developments, and the existing vendor landscape. Such market insights can be accomplished with this comprehensive Global Bone Marrow-Derived Stem Cells (BMSCS) Market research report which takes into account all the aspects of current and future market. The report provides wide-ranging analysis of the market structure along with the estimations of the various segments and sub-segments of the market. This Global Bone Marrow-Derived Stem Cells (BMSCS) Market research report delivers an analytical measurement of the main challenges faced bythe business currently and in the upcoming years.

Bone marrow-derivedstem cells(BMSCS) marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to growing at a CAGR of 10.4% in the above-mentioned forecast period. Increasing awareness regarding the benefits associates with the preservation of bone marrow derived stem cells will boost the growth of the market.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bone-marrow-derived-stem-cells-bmscs-market

The major players covered in the bone marrow-derived stem cells (BMSCS) market report are CBR Systems, Inc, Cordlife Sciences India Pvt. Ltd., Cryo-Cell International, Inc.ESPERITE N.V., LifeCell International Pvt. Ltd., StemCyte India Therapeutics Pvt. Ltd, PerkinElmer Inc, Global Cord Blood Corporation., Smart Cells International Ltd., Vita 34 among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Some of the factors such as introduction of novel technologies for the preservation of stem cells and their storage, surging investment that will help in research activities leading to stem cells benefits, adoption of hemotopoietic stem cell transplantation system will accelerate the growth of the bone marrow-derived stem cells (BMSCS) market in the forecast period of 2020-2027. Various factors that will create opportunities in the bone marrow-derived stem cells (BMSCS) market are increasing occurrences of various diseases along with rising applications in emerging economies.

Large cost of operation and strict regulatory framework will restrict the growth of bone marrow-derived stem cells (BMSCS) market in the above mentioned forecast period. Ethical concern leading to stem cells will become the biggest challenge in the market growth.

Global Bone Marrow-Derived Stem Cells (BMSCS) Market By Service Type (Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation), Application (Personalized Banking Applications, Research Applications, Clinical Applications), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027

Global Bone Marrow-Derived Stem Cells (BMSCS) Market Scope and Market Size

Bone marrow-derivedstem cells(BMSCS) market is segmented on the basis of service type and application. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Thisbonemarrow-derived stem cells (BMSCS) market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on bone marrow-derived stem cells (BMSCS) market contactData Bridge Market Researchfor anAnalyst Brief, our team will help you take an informed market decision to achieve market growth.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-bone-marrow-derived-stem-cells-bmscs-market

Bone Marrow-Derived Stem Cells (BMSCS) Market Country Level Analysis

Bone marrow-derivedstem cells(BMSCS) market is analysed and market size insights and trends are provided by country, service type and application as referenced above.

The country section of the bone marrow-derivedstem cells(BMSCS) market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

Bone marrow-derived stem cells (BMSCS) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for bone marrow-derived stem cells (BMSCS) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the bone marrow-derived stem cells (BMSCS) market. The data is available for historic period 2010 to 2018.

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-bone-marrow-derived-stem-cells-bmscs-market

Key Highlights of Report

Competitive Landscape and Bone Marrow-Derived Stem Cells (BMSCS) Market Share Analysis

Bone marrow-derived stem cells (BMSCS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to bone marrow-derived stem cells (BMSCS) market.

Get Registered For Digital Conference @https://www.databridgemarketresearch.com/digital-conference/future-of-healthcare-robotics?pm

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Read more here:
Global Bone Marrow-Derived Stem Cells (BMSCS) Market (COVID 19 Impact Analysis) Data Highlighting Major Vendors, Promising Regions, Anticipated Growth...

This Global Bone Marrow-Derived Stem Cells (BMSCS) Market research report involves a key data and information about the market, emerging trends, product usage, motivating factors for customers and competitors, restraints, brand positioning, and customer behaviour, which is of utmost importance when it comes to achieving a success in the competitive marketplace. Thus, the report deals with plentiful aspects of the industry. This market report provides with CAGR value fluctuation during the forecast period of 2020 2027 for the market. SWOT analysis is the standard, renowned and full-proof method to conduct the market research study which is used to formulate this particular Global Bone Marrow-Derived Stem Cells (BMSCS) Market report.

Global Bone Marrow-Derived Stem Cells (BMSCS) Market By Service Type (Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation), Application (Personalized Banking Applications, Research Applications, Clinical Applications), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027

By providing an absolute overview of the market, Global Bone Marrow-Derived Stem Cells (BMSCS) Market report covers various aspects of market analysis, product definition, market segmentation, key developments, and the existing vendor landscape. Such market insights can be accomplished with this comprehensive Global Bone Marrow-Derived Stem Cells (BMSCS) Market research report which takes into account all the aspects of current and future market. The report provides wide-ranging analysis of the market structure along with the estimations of the various segments and sub-segments of the market. This Global Bone Marrow-Derived Stem Cells (BMSCS) Market research report delivers an analytical measurement of the main challenges faced bythe business currently and in the upcoming years.

Bone marrow-derivedstem cells(BMSCS) marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to growing at a CAGR of 10.4% in the above-mentioned forecast period. Increasing awareness regarding the benefits associates with the preservation of bone marrow derived stem cells will boost the growth of the market.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bone-marrow-derived-stem-cells-bmscs-market

The major players covered in the bone marrow-derived stem cells (BMSCS) market report are CBR Systems, Inc, Cordlife Sciences India Pvt. Ltd., Cryo-Cell International, Inc.ESPERITE N.V., LifeCell International Pvt. Ltd., StemCyte India Therapeutics Pvt. Ltd, PerkinElmer Inc, Global Cord Blood Corporation., Smart Cells International Ltd., Vita 34 among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Some of the factors such as introduction of novel technologies for the preservation of stem cells and their storage, surging investment that will help in research activities leading to stem cells benefits, adoption of hemotopoietic stem cell transplantation system will accelerate the growth of the bone marrow-derived stem cells (BMSCS) market in the forecast period of 2020-2027. Various factors that will create opportunities in the bone marrow-derived stem cells (BMSCS) market are increasing occurrences of various diseases along with rising applications in emerging economies.

Large cost of operation and strict regulatory framework will restrict the growth of bone marrow-derived stem cells (BMSCS) market in the above mentioned forecast period. Ethical concern leading to stem cells will become the biggest challenge in the market growth.

Global Bone Marrow-Derived Stem Cells (BMSCS) Market By Service Type (Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation), Application (Personalized Banking Applications, Research Applications, Clinical Applications), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027

Global Bone Marrow-Derived Stem Cells (BMSCS) Market Scope and Market Size

Bone marrow-derivedstem cells(BMSCS) market is segmented on the basis of service type and application. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Thisbonemarrow-derived stem cells (BMSCS) market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on bone marrow-derived stem cells (BMSCS) market contactData Bridge Market Researchfor anAnalyst Brief, our team will help you take an informed market decision to achieve market growth.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-bone-marrow-derived-stem-cells-bmscs-market

Bone Marrow-Derived Stem Cells (BMSCS) Market Country Level Analysis

Bone marrow-derivedstem cells(BMSCS) market is analysed and market size insights and trends are provided by country, service type and application as referenced above.

The country section of the bone marrow-derivedstem cells(BMSCS) market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

Bone marrow-derived stem cells (BMSCS) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for bone marrow-derived stem cells (BMSCS) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the bone marrow-derived stem cells (BMSCS) market. The data is available for historic period 2010 to 2018.

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-bone-marrow-derived-stem-cells-bmscs-market

Key Highlights of Report

Competitive Landscape and Bone Marrow-Derived Stem Cells (BMSCS) Market Share Analysis

Bone marrow-derived stem cells (BMSCS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to bone marrow-derived stem cells (BMSCS) market.

Get Registered For Digital Conference @https://www.databridgemarketresearch.com/digital-conference/future-of-healthcare-robotics?pm

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Read more here:
Global Bone Marrow-Derived Stem Cells (BMSCS) Market Analysis 2020 With COVID 19 Impact Analysis| Leading Players, Industry Updates, Future Growth,...

The "Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

The stem cell therapy market was valued at US$ 1,534.55 million in 2019 and is estimated to reach US$ 5,129.66 million by 2027; it is expected to grow at a CAGR of 16.7% from 2020 to 2027.

The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market. However, high cost related of the stem cell therapy limits the growth of the market.

Stem cell research has been widely investigated globally for various medical applications, especially for the treatment of humans. This raises the importance of creating public awareness about stem cell research and its clinical potential. The main role of stem cells is in the replacement of dying cells and reconstruction of damaged tissues. Based on the extensive stem cell research, many scientists have claimed that these cells could probably be used in the treatment of various diseases, including cancer and cardiovascular disease.

There is a large number of potential treatment procedures that are undergoing clinical trials, and a notably few stem cell therapies have won FDA (i.e., US -Food and Drug Administration) approval for clinical usage. For instance, in 2019, the FDA approved Fedratinib for the first-line treatment for myelofibrosis. Moreover, stem cell therapies are widely used in bone marrow transplantation, and these therapies have benefited thousands of people suffering from leukemia. Hematopoietic stem cells are used for treating more than 80 medical diseases, including immune system disorders, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and several types of cancers, such as leukemia and lymphoma; this is also likely to boost the demand for this treatment procedure during the forecast period. Researchers are further investigating the use of stem cell therapies in the treatment of autoimmune disorders.

The global stem cell therapy market has been segmented on the basis of type, treatment, application type, and end user. Based on type, the market has been segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and others. The adult stem cell therapy held the largest share of the market in 2019; however, induced pluripotent stem cell therapy is estimated to register the highest CAGR in the market during the forecast period. Based on treatment, the stem cell therapy market has been segmented into allogeneic and autologous. The allogeneic segment held a larger share of the market in 2019; however, the market for the autologous segment is expected to grow at a higher CAGR during the forecast period.

Reasons to Buy:

Market Dynamics

Drivers

Restraints

Opportunities

Future Trends

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/kn7iuy

View source version on businesswire.com: https://www.businesswire.com/news/home/20200615005447/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

See the article here:
Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts - ResearchAndMarkets.com - Yahoo Finance

When Dr Yendry Ventura began work to set up the Abu Dhabi Stem Cell Centre in late 2018, there was, he says, nothing else "related to stem cell therapy in the emirate.

Fast forward to today and the situation has changed dramatically. After opening in December last year, the centre has already received international press coverage over to its research into a treatment for Covid-19.

Their groundbreaking work has involved taking stem cells from a patients blood and returning them, via a nebuliser, as a fine mist to the lungs.

There they help regenerate lung cells and improve the body's immune response by preventing an overreaction to the infection that can damage healthy cells.

What characterises the method, says Dr Ventura, is that very little manipulation of the cells is needed for the treatment to be effective.

The future for the stem cells lies in regenerative medicine, in which you can treat almost all the degenerative conditions.

Dr Yendry Ventura

We separate a specific layer of cells from the blood, Dr Ventura told The National. Were the first one to use these cells with this route with this method.

We believe this way the cells can be aimed much better to the affected organs - the upper and lower respiratory tract.

In April, the centres efforts to develop a Covid-19 treatment led to the recovery of all 73 patients the treatment was initially trialled on. A quarter had been in intensive care.

The results appeared so promising that this month the centre secured intellectual property rights to the technique, allowing the treatment to be widely licensed, including to facilities abroad.

The ongoing work exemplifies how the centres specialists have been able to apply their expertise to help in a time of crisis, Dr Ventura said.

But the new research is a departure from the facilitys usual purpose, which involves developing cutting-edge stem cell treatments for conditions such as cancer and heart disease.

Stem cells were first extracted from humans and grown in laboratories less than a quarter of a century ago.

The human body is mostly made of specialised cell types, such as heart muscle cells, kidney cells or nerve cells, all of which have a particular form related to their function.

Stem cells, however, have not yet undergone the process of developing into a specialised cell type, and are able to be manipulated to perform a specific function.

In adults, stem cells are found in tissues including fat and bone marrow, and these can be turned into cell types.

One technique that the Abu Dhabi Stem Cell Centre plans to implement is haematopoietic stem cell transplantation, which involves stem cells being removed from an individual who is due to have cancer treatment.

The cells are then processed in a laboratory and injected into the patient after they have undergone chemotherapy or radiotherapy.

In this way, they can replace stem cells destroyed by the treatment, allowing a patient to tolerate a higher dose of therapy.

Dr Ventura says that similar treatments were applicable to most cancers of the blood as well as cancers that produce solid tumours.

There are many of these therapies still in research stage, but if you conquer this research, you can have a programme in which you can ... treat many kinds of cancers at the same time in one centre, he said.

The reality is that cell therapy is curing cancer We need to improve this therapy and make it available for many other people.

The future for the stem cells lies in regenerative medicine, in which you can treat almost all the degenerative conditions.

You can create in the future, if you have the right technologies, even artificial organs.

Set up with private sector funding in collaboration with the UAE authorities, the Abu Dhabi Stem Cell Centre works closely with experts at Sheikh Khalifa Medical City.

But the institution is keen to forge further partnerships with both public and private sector medical institutions.

Currently, it operates seven days a week and has more than 100 staff, including nurses, technicians and doctors who specialise in immunology, haematology, pathology, orthopaedics, urology and radiology.

In another initiative, the facility has recently begun running Minimal Residual Disease tests, which look at how many malignant cells remain in a patients blood or bone marrow.

These tests are useful for people with a variety of blood cancers, including lymphoma, leukaemia and myeloma. But they require fresh samples from the patient, so the lack of UAE testing facilities has, until now, required patients to travel abroad.

We try to implement the tests here in the Abu Dhabi Stem Cell Centre so that the patient does not need to travel anymore, said Dr Ventura.

Updated: June 16, 2020 02:01 PM

The rest is here:
Coronavirus: inside the UAE stem cell centre working to treat Covid-19 - The National

Hematopoietic Stem Cell Transplantation (HSCT) Market report provide the COVID19 Outbreak Impact analysis of key factors influencing the growth of the market Size (Production, Value and Consumption). This Hematopoietic Stem Cell Transplantation (HSCT) industry splits the breakdown (data status 2014-2020 and Six years forecast 2020-2026), by manufacturers, region, type and application. This study also analyses the Hematopoietic Stem Cell Transplantation (HSCT) market Status, Market Share, Growth Rate, Future Trends, Market Drivers, Opportunities and Challenges, Risks and Entry Barriers, Sales Channels, Distributors and Porters Five Forces Analysis.

Hematopoietic Stem Cell Transplantation (HSCT) Market competitive landscapes provides details by topmost manufactures like (Regen Biopharma Inc, China Cord Blood Corp, CBR Systems Inc, Escape Therapeutics Inc, Cryo-Save AG, Lonza Group Ltd, Pluristem Therapeutics Inc, ViaCord Inc), including Capacity, Production, Price, Revenue, Cost, Gross, Gross Margin, Growth Rate, Import, Export, Market Share and Technological Developments

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures)of Hematopoietic Stem Cell Transplantation (HSCT)[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2276986

Hematopoietic Stem Cell Transplantation (HSCT) Market Competition by Manufacturers (2020 2026): Hematopoietic Stem Cell Transplantation (HSCT) Market Share of Top 3 and Top 5 Manufacturers, Hematopoietic Stem Cell Transplantation (HSCT) Market by Capacity, Production and Share by Manufacturers, Revenue and Share by Manufacturers, Average Price by Manufacturers By Market, Manufacturers Manufacturing Base Distribution, Sales Area, Product Type, Market Competitive Situation and Trends, Market Concentration Rate.

Scope of Hematopoietic Stem Cell Transplantation (HSCT) Market:In 2019, the market size of Hematopoietic Stem Cell Transplantation (HSCT) is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Hematopoietic Stem Cell Transplantation (HSCT).

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Allogeneic Autologous

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

Peripheral Blood Stem Cells Transplant (PBSCT) Bone Marrow Transplant (BMT) Cord Blood Transplant (CBT)

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2276986

Hematopoietic Stem Cell Transplantation (HSCT) Market: Regional analysis includes:

The Study Objectives Of This Hematopoietic Stem Cell Transplantation (HSCT) Market Report Are:

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

See the original post here:
Hematopoietic Stem Cell Transplantation (HSCT) Market Segments, Opportunity, Growth and Forecast by End-use Idustry 2020-2026 - Cole of Duty

The speed of change is fascinating

As we head into the 2020s, tech developers and medical scientists are working hard to ensure that we stay healthy and well-cared for, for as long as possible. Here are some of the big healthcare innovations making waves at the moment.

Artificial blood has been proposed for a number of years, but it is only recently that it has gained any sort of traction in medical circles. The science behind it is simple to understand while no doubt actually being incredibly complex. Artificial blood does not seek to replace blood entirely but instead to supplement red blood cells in the body, to carry oxygen where it needs to be delivered.

These blood cells are called artificial as they are generated in a lab environment instead of a human body and are grown from stem cells. Researchers typically use hematopoietic stem cells taken from bone marrow for growing such cells. With blood donation dropping, this could be a timely solution to support healthcare professionals alongside blood donation drives.

Blindness is a massive issue no matter where you live on the planet. In particular, corneal blindness is the fourth most common blindness in the world. However, there is now a solution that is cheap and easy to deliver, and that could make a massive difference to many people.

Many are now coming forward to support medical staff in their endeavours in this sector. Tej and Wendy Kohli are key voices in creating help here. Following other charitable givers like Bill and Melissa Gates and Warren Buffett, it is clear that input from top figures like this is crucial in supporting a cause and seeing it develop into a system that could genuinely make a difference.

The ability to use genetic information to come up with a treatment plan for a patient is a precise art. However, research into the world of genomics is making this a much more viable method of treatment than it has previously.

The scope for this is massive. So much of our response to certain treatments can be bound up in our genetics and research here could change medicine forever. With setbacks like organ transplant rejection and gene mutation still having a major impact on medicine as a whole, it is incredibly important that researchers work to find a solution that works around these issues. Comprehensive and detailed genomics might be it.

All three of these areas have seen some massive leaps forward in the past month. No matter what, focus needs to be kept on these key areas in the future. Only then will we see some massive improvements that could shape our healthcare for the better. These developments could lead to the complex becoming the norm in worldwide healthcare.

Developments made today might one day be celebrated as pioneering breakthroughs that helped to transform healthcare and the lives of humanity.

Here is the original post:
Healthcare innovations making waves in 2020 - Crawley Observer

People with cancer may have compromised immunity due to their disease or its treatment. Early reports suggest cancer is a risk factor for severe COVID-19 disease as a result, many patients with cancer, and their families, are concerned about the risks and impacts of COVID-19.

Their concerns and distress are likely to be compounded by extensive media coverage of the pandemic, rapid changes in information about COVID-19 and continuing uncertainty about how to contain the disease.

On top of this, community transmission of COVID-19 has threatened the capacity of cancer services to provide routine investigations and care. In some cases, this has seen a prioritisation or modification of patients cancer therapies.

For example, chemotherapy may be postponed as this can compromise the immune system and make patients more vulnerable to developing COVID-19 disease.

Patients and families may, in turn, be frightened about not receiving proper treatment.

Read more

Another cause for concern is the change in the routine clinical management of cancer patients, partly because patients fear being infected. In Victoria, cancer hospitals have reported a 40 per cent decline in patient presentations for cancer management appointments since the stay-at-home guidelines in late March 2020.

This has raised concern among oncology health professionals about the health and wellbeing of vulnerable cancer patients whose health outcomes are likely to be negatively affected.

As patients are presenting less to hospital, it becomes crucial to develop new ways of identifying any distress in order to provide high-quality cancer management and supportive care.

The restrictions imposed by governments have been effective in limiting the spread of COVID-19, but social distancing, quarantine and visitor limitations have also reduced the opportunity for family support and connection important sources of strength and wellbeing.

These same government restrictions have also increased the use of telehealth to deliver care to cancer patients during COVID-19. Telehealth tools include simple patient health portal messages to relieve triage phone lines, e-consultation and telephone or video-based virtual visits.

Read more

The latest data from the Victorian COVID-19 Cancer Networks Telehealth Expert Group found that all of Victorias health services were now using telehealth for cancer care. And these tools may continue to expand, allowing greater access to supportive care beyond this crisis.

However, as useful as it is, this technology may pose issues of trust, isolation, disconnectedness and worries about abandonment as patients no longer benefit from the reassuring structure of the hospital oncology setting.

Telehealth may also not be possible for patients without a computer or internet access, which may create inequities in psychosocial care.

These issues should be considered if we upscale telehealth procedures for cancer patients and want to keep the best changes after the pandemic.

With respect to COVID-19, people with blood cancer are a particularly vulnerable group and require specialised attention and care. This is because blood cancers affect the production and functions of cells created in the bone marrow, which produces all the cells of our immune system.

Additionally, treatment for blood cancers compromise the immune system further, placing patients at very high risk of opportunistic infections, often for an extended period.

Read more

Even common respiratory viruses, like colds, can threaten survival. As a result, blood cancer specialists have recommended heightened surveillance and protective isolation for people with blood cancers.

A second major issue for blood cancer patients during the COVID-19 pandemic is the availability of donor stem cell products for patients undergoing haematopoietic stem cell transplantation.

Approximately 350 stem cell transplants are performed in Australia every year to treat blood cancers like leukaemia and multiple myeloma.

But finding a suitable stem cell donor is incredibly challenging, and about 80 per cent of donated stem cells come from overseas donors.

Unfortunately, COVID-19 has impacted donor availability due to border restrictions, flight changes and fear of becoming infected, creating very fearful scenarios for those waiting for potentially life-saving stem cell transplantation.

Victoria has already reported a case of a donor cancellation at short notice because the donor was worried about having been in contact with somebody with COVID-19.

The emotional consequences of the COVID-19 pandemic for people with blood cancers cannot be underestimated, nor can the consequences for the healthcare providers who care for them.

Read more

The COVID-19 pandemic has had a serious and disruptive effect.

In the short term, staff and resources at many hospitals have been reassigned to manage the rush of patients with COVID-19. Healthcare providers are faced with ethical dilemmas and required to make difficult treatment decisions without evidence-based guidelines.

Estimating the risk versus the benefit of administering potentially immunosuppressive treatment to patients with haematological cancers with a scarcity of knowledge about this novel disease, and balancing the individual and societal benefits with stretched resources, poses acute ethical dilemmas.

Making these challenging decisions can create fertile grounds for burnout and trauma.

More than ever, we need to develop ways to nurture healthcare providers.

Consideration of their unique experiences and needs during these exceptionally difficult times is important and we need to flexibly develop services to respond to those needs now and beyond this crisis.

But in developing such services, as well as recognising unmet needs, we have to acknowledge the problem-solving skills, resourcefulness and innovation that patients and healthcare providers have already undertaken as they have strived to adapt to managing cancer during COVID-19.

Banner: Getty Images

Read this article:
COVID-19 and cancer care - Pursuit